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Abstract
Introduction. We investigated the effect angiotensin II (Ang II), a corpus cavernosal smooth muscle (CCSM) constrictor peptide, has
on tissue taken from rabbits following chronic partial bladder outlet obstruction (PBOO), since this model is characterised by an
increase in corpus cavernosal collagen deposition and a marked reduction and impaired relaxation of CCSM cells.
Aim. To determine the interaction between Ang II and nitric oxide (NO) and the development of oxidative stress (OS) in a rabbit
model of chronic PBOO.
Methods. Corpus cavernosal tissue was obtained from 12 sham-operated and 20 PBOO rabbits. Organ bath studies determined Ang
II/NO interaction on CCSM function using losartan (AT1 receptor antagonist), sodium nitroprusside (SNP, NO donor), electrical field
stimulation
 (EFS) and vardenafil (PDE5 inhibitor). The role of OS in the Ang II response was also determined using diphenyene
iodonium chloride (DPI) the NAD(P)H oxidase inhibitor, which inhibits superoxide production and superoxide dismutase (SOD, the
enzyme that accelerates the breakdown of superoxide).
Main Outcome Measure. Action of Ang II, AT1 receptor antagonist, as well as SOD and DPI on CCSM function.
Results.  Ang II caused a dose dependent contraction of CCSM strips that was enhanced in PBOO rabbits and inhibited by losartan,
DPI and SOD. CCSM relaxation induced by SNP/EFS was impaired in this model and improved by vardenafil and losartan.
Conclusions.  These findings imply that the increased Ang II contractile response is a pathological consequence of PBOO and that
AT1 receptor inhibition may be a therapeutic approach to treat ED associated with PBOO.
Key Words. Angiotensin II; Losartan; Corpus Cavernosum Contraction; Partial Bladder Outlet Obstruction; Oxidative Stress; Benign
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Introduction
It is now recognised that benign prostatic hyperplasia (BPH) can cause partial bladder outlet obstruction (PBOO),1
resulting in structural and functional changes to the bladder that can influence the storage and emptying of urine, with many patients
developing detrusor overactivity.2  The clinical consequences of PBOO associated with BPH3, including urodynamics and structural
changes in bladder pathophysiology can be reproduced in animal models, by tying a ligature around the proximal urethra at the base of
the bladder neck. 4,5   An increase in bladder mass, as well as hypertrophy and hyperplasia of bladder smooth muscle, with thickening
of the outer serosal layer have been reported in rabbits following this procedure. 5 Functional studies have also revealed a reduction in
3electrical field stimulation (EFS) and chemical-induced bladder smooth muscle contraction, 6 supporting the clinical findings of
impaired bladder function following PBOO.
There has been a continuing debate as to whether there is a link between BPH and erectile dysfunction (ED). Although
some clinical studies suggest an association,7,8 where sexual performance is related to the severity of BPH9, a literature based study
could not identify this link.10 However, the use of the PBOO animal model has helped to investigate this association.11,12  We were the
first to show increased collagen deposition in the corpus cavernosum13 and preliminary evidence of impaired corpus cavernosal
smooth muscle (CCSM) relaxation in a chronic PBOO rabbit model,14,15 . This has been substantiated by the findings that
endothelium-dependent (ACh-mediated) and  endothelium-independent (ATP/ sodium nitroprusside [SNP]-mediated) CCSM
relaxation is impaired, with a marked reduction in smooth muscle cells in this model.12 These findings imply that PBOO animals
exhibit many of the features of ED and offer a test bed to determine its influence on other components of the erectile process, for
example pro-contractile mechanisms, which terminate penile erection by keeping the smooth muscle of the penile arteries and
trabeculae contracted.16 This is of particular importance, since unlike most smooth muscle cells those of the corpus cavernosum spend
the majority of the time contracted. 11
Angiotensin II (Ang II), a bioactive octapeptide, is one such mediator of human CCSM contractility and tone. 17 This is
supported by the finding that human corpus cavernosum produces and secretes physiological amounts of Ang II18 and healthy men
produce Ang II corpus cavernosal blood levels that are higher during penile detumescence compared with the tumescence phase.19
Although the physiological actions of Ang II are mediated via AT1 and AT2 receptors, 20 in regards to the corpus cavernosum, human
and rabbit studies have found activation of AT1 and not AT2 receptors elicit smooth muscle contraction, a response that can be
blocked by AT1 receptor antagonists.17,21  It is now clear that Ang II plays an important role in modulating the tone of human penile
arteries and trabecular smooth muscle and that its regulation is governed by a balance with NO. 17 NO antagonises the vasoconstrictive
and pro-atherosclerotic effect of Ang II, whereas Ang II decreases NO bioavailability by promoting oxidative stress (OS). 17,22  Ang II
upregulates the production of superoxide (O2– ; one of the reactive oxygen species elevated in OS), in endothelial and vascular smooth
muscle, which is thought to directly contribute to Ang II-induced smooth muscle contraction.23
Here, we determined the effect Ang II, AT1 receptor inhibition and OS have on CCSM contractility, together with their
modulation of NO-mediated relaxation in a chronic rabbit model of PBOO. The results from this study provide important information
on the pathological role of Ang II in ED.
Methods
Induction of partial bladder outlet obstruction (PBOO)
Twenty 3kg adult male New Zealand White rabbits purchased from Highgate Farm (UK Home Office accredited source)
underwent PBOO. Twelve age-matched, sham-operated rabbits formed the control group. All animal were fed ad libitum with SDS
standard plain diet (SDS, Witham, UK) and allowed free access to water.
To create PBOO, each rabbit received a general anaesthetic (1-2% halothane in O2) and was then placed on a heating pad
regulated at 370C. The abdomen was shaved and the operative site sterilised with betadine. A urinary balloon catheter (Foley, C.R.
4Bard international Ltd, Crawley, UK) size 8 Fr gauge was inserted into the penile urethra and inflated inside the bladder. The bladder
and proximal urethra was exposed following a lower midline laparotomy and cleared of fat and connective tissue. A 2-0 silk ligature
was placed loosely around the catheterised proximal urethra at the base of the bladder neck. The bladder was then returned to the
peritoneal cavity and the wound closed in layers. The laparotomy incision was closed with continuous stitching using 4-0 vicryl suture
and the skin closed with subcuticular stitching using 4-0 vicryl suture. The catheter was then removed and the rabbit allowed to
recover. Pain medication (buprenorphine, 0.1 mg/kg im, twice daily for 2 days) and antibiotics (enrofloxacin, 10 mg/kg im, twice
daily for 5 days pre- and post-operatively) was administered to each rabbit. Sham-operated rabbits underwent the same surgical
procedure without tying the ligature around the proximal urethra. All procedures were conducted under an approved Home Office
Project Licence. After 8 weeks the sham-operated and PBOO rabbits were killed by cervical dislocation (using a method permitted by
the Home Office). The penis was rapidly excised from each rabbit and placed in cold oxygenated Krebs solution at 40C for the organ
bath studies.
            All rabbit penile tissue preparations were investigated on the same day of tissue acquisition.
Tissue acquisition
Fat and connective tissue was removed from the rabbit penis and the tunica albuginea opened. The corpus cavernosum was
removed and cut into strips of approximately 1x3x1 mm. Tissue strips were taken from at least 3 animals for each experiment.
Organ bath studies
The tissue strips were mounted vertically in 10 ml organ baths, equipped with two parallel platinum electrodes for EFS.
Tissues were bathed with Krebs solution and maintained at 370C by a thermoregulated circuit and bubbled with a mixture of 95% O2 /
5% CO2. The Krebs solution was made up of NaCl 120 mM, NaHCO3 25.6 mM, KCl 4.7 mM, CaCl2 2.5 mM, NaH2PO4 1.2 mM and
glucose 22 mM with a pH of 7.4. A 2g tension was applied to the suspended tissue strips and left for 1h to equilibrate (tension
recorded on a Grass Polygraph, model 7D; Astro-med Grass, Slough, UK).
Effects
Bladder weights: The bladders were excised from sham-operated and PBOO rabbits after 8 weeks and weighed.
Ang II. The effect of Ang II (10-8M – 10-5M) on CCSM function was investigated using tissue strips from sham-operated and PBOO
rabbits.
Ang II receptor antagonists. After the effect of Ang II on tissue strips taken from sham-operated and PBOO rabbits were
determined; the tissues were washed over a 30 min period and exposed to losartan (10-5 M, AT1 antagonist) for 20 min before
repeating the Ang II response. The effect of the vehicle (distilled water for 20 min) on the Ang II response was also determined.
Oxidative Stress
DPI . The effect diphenyene iodonium chloride made up in DMSO (DPI, 10-4M, NAD(P)H oxidase inhibitor, which inhibits •O2–
5production)  has on the Ang II (10-6M) response from sham-operated and PBOO tissue strips was determined.
SOD. The effect superoxide dismutase (SOD, 200 IU/ml; the enzyme that accelerates the breakdown of •O2–) has on the Ang II (10-
6M) response from sham-operated and PBOO tissue strips was also determined.
Electrical Field Stimulation
NANC neurotransmission. In a series of experiments CCSM tissue from sham-operated and PBOO animals were exposed to
guanethidine (5 x 10-6 M), atropine (10-5 M) and indomethacin (10-6 M), which were added to the bathing solution and left for 20 min
to inhibit the adrenergic, cholinergic and cyclo-oxygenase pathways, respectively, leaving the NANC pathway intact. The tissue strips
were then pre-contracted with PE followed by EFS of penile nerves with a Grass S88 (Astro-med Grass, Slough, UK) stimulator. The
stimulator delivered single square waves (duration 0.4 ms; 20V) at a frequency of 8.0 Hz in 5 s trains. Losartan and DPI was then
added and the EFS repeated.
We choose 8 Hz since this stimulation frequency is ideal to evaluate the effect of losartan on NANC neurotransmission. 17
Sodium Nitroprusside
CCSM tissue strips from sham-operated and PBOO rabbits were pre-contracted with PE (10-4M) and cumulative response curves were
constructed for the NO donor SNP, 10-7 – 3x10-6 M).
Vardenafil. After constructing the SNP cumulative response curve the strips were washed several times followed by the addition of
vardenafil, (10-8 M; PDE 5 inhibitor, a cGMP-specific phosphodiesterase type 5 inhibitor, which inhibits the hydrolysis of cGMP to
5’- GMP) to the organ bath for 20 min. The tissues were re-contracted with PE and cumulative response curves were again constructed
for SNP. The stock solution of vardenafil (10-3 M) was made up in acid water pH 4.5 and subsequently diluted in distilled water before
adding to the organ bath. We found that the final dilution of acid had no effect on SNP-induced relaxation.
Losartan. In another series of experiments SNP cumulative response curves were again constructed using CCSM tissue from PBOO
animals. The tissue was washed several times before the addition of losartan (10-5 M) to the organ bath for 20 min and re-contracted
with PE and a cumulative response curve constructed for SNP.
Statistical Method
Results were analysed and expressed as mean ± SEM using Graph Pad Prism 3.0 software. Ang II tissue responses were expressed as
mg tension / mg tissue. EFS and SNP tissue responses were expressed as % relaxation of PE-induced tone. Comparisons of the Ang II
dose response curves and SNP cumulative dose response curves were made using analysis of variance (2 way ANOVA, p < 0.05).
Statistical analysis was determined using a Student’s unpaired and paired t-test with statistical significance accepted at p < 0.05.
Results
Bladder weights
There was a significant increase in 8 weeks PBOO rabbit bladder weights when compared with sham-operated animals (sham-
operated rabbits, 2.1 ± 0.1g vs PBOO rabbits, 23.2 ± 2.5g; n =13 p<0.0001 Student’s unpaired t-test).
6Ang II and CCSM contraction
The size and weight of cavernosal strips from sham-operated and PBOO rabbits were similar. Ang II caused a dose dependent
contraction (10-8M – 10-5M) of CCSM strips from sham-operated and PBOO rabbits, which was markedly increased in the PBOO
group and reduced by losartan (Fig 1). The addition of the vehicle did not significantly influence the Ang II response in any
experiment.
Oxidative Stress
CCSM contraction. DPI and SOD reduced the Ang II-induced contraction of CCSM strips from sham-operated and PBOO rabbits,
Fig 2.
CCSM relaxation. EFS-induced CCSM relaxation of sham-operated and PBOO strips, was increased following adrenergic,
cholinergic and cyclo-oxygenase inhibition and in the presence of losartan (Fig 3). In addition, EFS-induced CCSM relaxation of
PBOO strips was increased by 18.4% following addition of the triple inhibitors (guanethidine, atropine and indomethacin), and in the
presence of DPI.
SNP and CCSM relaxation
SNP-induced relaxation of CCSM strips taken from PBOO rabbits was impaired compared with sham-operated animals and improved
by vardenafil (Fig 4) and losartan (Fig 5).
Discussion
This study shows, for the first time, a dose dependent enhancement of the Ang II-induced contraction of CCSM tissue
taken from PBOO rabbits when compared with sham-operated controls. It also supports previous findings using human and rabbit
corpus CCSM tissue, which revealed the Ang II–mediated contractile response is due to AT1 receptor activation17,21 with the
development of OS.17
Under physiological conditions Ang II-containing cells in the endothelium of arterioles, as well as the endothelium lining
sinusoids and smooth muscle bundles of the corpus cavernosum, 17 secrete their Ang II content on adrenergic stimulation, keeping the
smooth muscle of the penile arteries and trabeculae contracted; a scenario that has added significance, since the CCSM cells spend the
majority of the time contracted during penile flaccidity/detumescence.
Previous in vivo experiments using anesthetised dogs have shown that intracavernosal injections of Ang II terminate
spontaneous erections. In contrast, losartan induced penile erections by relaxing CCSM, affecting tone and contractility of vascular
smooth muscle within the blood vessels embedded in the corporal bodies, as well as the corpus cavernosum itself.18
The present findings demonstrate that Ang II increases CCSM contraction as a pathological consequence of PBOO. We
have used only one concentration of Ang II on each individual tissue strip, since multiple application of Ang II to isolated human
arteries results in a marked desensitisation of the functional response (i.e. tachyphylaxis) 24. This phenomenon may explain the large
variation in the Ang II 10-5M error bar following PBOO (Fig 1).
7Results from previous studies using PE as a mediator of CCSM contractility following PBOO in rabbits are inconclusive.
Chang et al., 11 noted a 50% increase in CCSM contractile force after 2 weeks PBOO, due to an increase in smooth muscle bundles and
cellular alterations in the contractile myosin-isoform composition. This increased contractility was not evident in the studies of Demir
et al., 25 and Lin et al., 12 at a similar time point, possibly due to post-operative inflammation in the sham-operated group and a
reduction in CCSM cells, respectively. Results from chronic PBOO studies have revealed a time-dependent change in the contractile
response. Demir et al., 25 found an increase in CCSM contractility after 4 weeks PBOO, as the inflammatory response in the sham-
operated group subsided. Whereas, Lin et al., 12 found the contractile response was reduced at 8 weeks, due to a reduction in CCSM
content and an increase in collagen deposition.
 In an attempt to shed more light on the changes in corpus cavernosal function following chronic PBOO, we conducted our
experiments using Ang II a known physiological mediator of human and rabbit CCSM contraction. Our data suggests that the
contractile capacity of each individual smooth muscle cell is increased in this model, even though the overall numbers are reduced due
to collagen deposition12, a finding that may have clinical relevance in the development of ED. This is in keeping with a previous study
that showed PE elicited an increased contractile response of CCSM strips taken from men with ED, suggesting an increase in corporal
vascular smooth muscle contractility may contribute to the pathophysiology of ED in older men. 26
The PBOO-induced augmentation of the Ang II pathway could be due to an increase in Ang II release and/or AT1 receptor
density, increased coupling efficiency of the agonist-receptor complex to the signal transduction machinery and/or increased
amplification of second messenger formation subsequent to receptor activation. While the importance of each potential mechanism is
uncertain, it is likely an increase in OS and excessive •O2– production is involved. The role of OS in the Ang II-mediated contraction
of human corpus cavernosum is known. 17 Ang II a potent stimulator of the smooth muscle enzyme NAD(P)H oxidase, stimulates the
production of •O2–.27 a mediator of Ang II-induced vasoconstriction.28 We found the selective NAD(P)H oxidase inhibitor DPI
significantly attenuated Ang II-induced CCSM contraction in sham-operated and PBOO rabbits. Although, the reduction in the Ang II
response induced by the •O2–   scavenger SOD was not significant, this trend particularly following PBOO suggests that SOD, similar
to DPI is capable of reducing OS. The effectiveness of these drugs is probably due to the abolishment of •O2–   generation. Similar
observations have been reported using vascular tissue, 23,29 while pyrogallol a generator of •O2– mimicked the Ang II enhancement.29
The interaction of •O2– with NO decreases NO bioavailability by promoting OS and generating the potent oxidative peroxynitrite
radical that reacts with proteins to produce tissue damaging nitrotyrosine, known to be elevated in PBOO. 30
NANC neurotransmission is an important component of penile erection, since stimulating the cavernous nerve leads to
smooth muscle relaxation. 31 This pathway is impaired following PBOO, 12 providing further evidence of the development of ED in this
model. Losartan significantly increased the EFS-induced relaxation of corpus cavernosal strips taken from PBOO rabbits following
cholinergic, prostaglandin and adrenergic inhibition. However, as Ang II release is via adrenergic stimulation, guanethidine should
have blocked this pathway making losartan ineffective. The data implies that guanethidine does not fully inhibit the adrenergic
pathway during EFS-induced relaxation, a point previously raised. 17
Our findings also confirm that SNP-mediated relaxation of CCSM tissue is impaired in chronic PBOO rabbits as
previously reported. 12,14   This reinforces the concept that this model demonstrates the salient features of ED. Vardenafil a member of
a family of PDE-5 inhibitors used to treat ED32-35, significantly improved the relaxation of CCSM strips taken from PBOO rabbits by
8reducing the degradation of cGMP and enhancing CCSM relaxation, suggesting the functional response to NO is intact. Similarly,
tadalafil another PDE-5 inhibitor increases the relaxant response to SNP of human vesicular-deferential arteries, which supply blood
to the bladder and prostate. 36 Losartan also significantly improved the SNP-mediated relaxation of CCSM strips taken from PBOO
rabbits, highlighting the interplay between Ang II and NO/cGMP, implying that an imbalance between these mediators is an important
factor in the development of ED. Interestingly, an inverse correlation between Ang II responsiveness and endothelium-dependent
relaxation has been demonstrated in isolated human arteries, which was related to the development of OS. 37
The actions of losartan may have clinical importance in ED management. For, although PDE 5 inhibitors have become
extremely effective oral agents for the treatment of ED, it has become increasingly apparent not all patients respond to this form of
therapy, 38 moreover, some who initially respond develop tachyphylaxis or discontinue their use due to loss of efficacy. 39 Thus, the use
of an Ang II antagonist, which reduce CCSM contractility, in conjunction with a PDE5 inhibitor may be beneficial for ED patients;
not only by reducing the percentage of none responders but also the concentration of PDE 5 inhibitor required to maintain erection.
This could explain, at least in part, why long-term losartan and PDE5 combination therapy has a beneficial effect on the structure and
function of CCSM tissue taken from spontaneously hypertensive rats. 40
In summary, Ang II causes a pathological enhancement of CCSM contraction from PBOO rabbits that was inhibited by
losartan, probably due to a direct/indirect reduction in •O2– production and OS. Losartan and vardenafil improved the impaired
SNP/EFS-mediated relaxation, providing important evidence of the interplay between Ang II and NO/cGMP pathways in the
regulation of CCSM tone. Elevated Ang II responsiveness, together with impaired relaxation of CCSM, may play a pivotal role in the
development of ED. Further studies are required to determine the molecular events responsible for the cellular changes to CCSM in
PBOO.
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NO nitric oxide
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OS oxidative stress
SNP sodium nitroprusside
SOD superoxide dismutase
PBOO partial bladder outlet obstruction
9PE phenylephrine
PDE 5 phosphodiesterase type 5
•O2– superoxide
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Figure 1. Ang II-induced contraction of CCSM strips taken from PBOO rabbits (■) was significantly (P<0.01) increased compared
with sham-operated animals (▲). The PBOO-induced increase in CCSM contractility was significantly reduced post-losartan (▼), P
<0.0001, n = at least 5 strips/concentration.
Figure 2. Ang II-induced contraction (10-6 M) of corpus cavernosal strips taken from sham-operated and PBOO rabbits was
significantly decreased post-DPI (10-4 M), * p<0.03, ** p=0.001 and not significant post-SOD (200UI/ml), n = at least 5 strips,
unpaired Student’s t-test.
Figure 3. EFS-induced relaxation of corpus cavernosal strips taken from sham-operated and PBOO rabbits at 8 Hz (following the
addition of guanethidine, atropine and indomethacin) was significantly increased post-losartan * p<0.02, n = at least 5 strips, paired
Student’s t-test.
Figure 4. SNP-induced relaxation of CCSM strips taken from PBOO (■) rabbits was significantly (P <0.0001) impaired compared
with sham-operated (▲) animals and was significantly improved post-vardenafil (▼), P<0.0001, n = at least 6 strips.
Figure 5. SNP-induced relaxation of CCSM strips taken from PBOO (■) rabbits was significantly (P <0.0001) impaired compared with
sham-operated (▼) animals and was significantly improved post -losartan (▲), P<0.01, n = at least 6 strips.
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 Introduction 
 Penile erection is a haemodynamic process involving 
increased arterial inflow and restricted venous outflow, 
co-ordinated with corpus cavernosum smooth muscle 
relaxation (CSMR). Although this process is generally ac-
cepted to be under neuroregulatory control, biochemical 
mediators released locally from the cavernosal endothe-
lium and/or smooth muscle also participates in initiating 
and maintaining an erection  [1] .
 It is now well established that nitric oxide (NO) re-
leased by the endothelium of the arteries that supply the 
penis as well as the corpus cavernosum and non-adren-
ergic, non-cholinergic (NANC) neurotransmission me-
diate CSMR through the formation of cyclic guanosine 
monophosphate cGMP  [2] , resulting in penile erection 
 [3–5] .
 Conversely, the erectile response is terminated when 
cGMP-specific phosphodiesterase catalyses the hydroly-
sis of cGMP to 5  -GMP, thus halting the cascade of reac-
tions and leading to smooth muscle contraction and con-
comitant detumescence  [6] . It is not unreasonable, there-
fore, that erectile dysfunction (ED) is often considered to 
be a situation where impaired CSMR has developed.
 ED is defined as the persistent inability to attain and 
maintain an erection adequate to permit satisfactory sex-
ual performance. It can affect up to 50% of men aged be-
 Key Words 
 Diabetic rabbits   Vardenafil   Impaired corpus cavernosal 
relaxation 
 Abstract 
 Introduction: Diabetes mellitus is associated with impaired 
cavernosal smooth muscle relaxation (CSMR) and the devel-
opment of erectile dysfunction (ED). Vardenafil, a phospho-
diesterase type 5 inhibitor has been used to treat ED. The aim 
of this study was to assess the in vitro and in vivo effects of 
vardenafil on diabetic rabbit CSMR.  Methods: Organ bath 
studies were used.  Results: Sodium nitroprusside (SNP)- and 
electrical field stimulation (EFS)-induced CSMR in diabetic 
rabbits given the vehicle was significantly impaired when 
compared with controls. The in vitro addition of vardenafil 
significantly enhanced SNP-induced CSMR in diabetic ani-
mals given the vehicle. SNP-induced CSMR in diabetic ani-
mals given in vivo vardenafil was significantly increased 
when compared with the diabetic untreated group. The in 
vitro addition of vardenafil significantly enhanced SNP and 
EFS-induced CSMR in cavernosal tissue taken from diabetic 
animals given vardenafil in vivo.  Conclusions: The present 
findings suggest that the combination of in vitro and in vivo 
vardenafil enhance diabetic CSMR, reinforcing the use of 
vardenafil for the treatment of diabetes-induced ED. 
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tween 40 and 70 years  [7] . Although not life-threatening, 
this common problem can significantly affect the quality 
of life as well as the psychological and social well-being 
of the sufferer.
 The prevalence of ED in diabetic men is up to 70%, 
highlighting the magnitude of the problem in this patient 
group  [8, 9] . Interestingly, neuronal and endothelium-de-
pendent-mediated CSMR have been reported to be im-
paired in diabetic patients with ED  [10] , which suggests 
an adverse affect on the NANC drive.
 In the past, pharmacological treatment of ED has been 
confined to intra-cavernosal  [11–13] and transurethral 
 [14] injections of drugs such as papaverine and prosta-
glandin E 1 . More recently, the family of phosphodiester-
ase type 5 (PDE-5) inhibitors (sildenafil, tadalafil and 
vardenafil) has been increasingly used to treat ED  [15–
17] . They enhance NO-induced cGMP accumulation re-
sulting in a significant relaxation of the corpus caverno-
sum  [16, 18] . The effect of these PDE-5 inhibitors is de-
pendent, at least in part, upon an intact NANC pathway.
 We previously used organ bath studies to determine 
whether PDE-5 inhibition (using sildenafil) enhances so-
dium nitroprusside (SNP)-induced relaxation of in vitro 
corpus cavernosal smooth muscle strips taken from dia-
betic rabbits  [18] .
 In the present study, we examine the effect in vitro ex-
posure of vardenafil (added to the organ bath) and/or 
chronically fed vardenafil (4 weeks’ in vivo treatment) 
has on CSMR.
 Method 
 Induction of Diabetes 
 Adult sexually mature male rabbits (n = 8) were injected intra-
venously with alloxan (65 mg/kg in a volume of 1 ml/kg), while 8 
control animals were injected with the saline vehicle alone (1 ml/
kg). Diabetic animals received 3 subcutaneous injections of 10 ml 
of 50% glucose, 4 h apart on the first day of alloxan treatment. A 
final glucose injection (10 ml of a 50% glucose solution) was ad-
ministered on the morning (7.30 a.m.) of the second day. This 
procedure was carried out to counteract the hypoglycaemia 
caused by insulin release from necrosed pancreatic beta cells due 
to the acute action of alloxan.
 Within 1 week of the alloxan injection, blood samples not ex-
ceeding more than 10% of the total blood volume were taken to 
confirm diabetes. Thereafter, blood samples not exceeding 15% 
of the total blood volume were taken at 4 and 6 months to monitor 
serum clinical biochemical variables.
 Experimental Animal Groups 
 After 6 months, the control and diabetic animals were divided 
into 4 groups.
 Group 1 (4 control rabbits) and group 2 (4 diabetic rabbits) 
were given vardenafil (3 mg/kg, Bayer Healthcare AG, Germany) 
made up in 120 ml HCl acid water pH 4.5 to drink each morning 
for  4  weeks,  this  was  followed  by  HCl acid water pH 4.5 given ad  
libitum.  Animals  in group 3 (4 control rabbits) and group 4 (4 
diabetic rabbits) received HCl acid water pH 4.5 to drink ad libi-
tum, for 4 weeks. The vardenafil dose (3 mg/kg) chosen has previ-
ously been shown to be the minimum dose required to elicit a 
significant reduction in the urological changes following partial 
bladder outlet obstruction in the rat  [19] . Rabbits in all four ex-
perimental groups readily drank the drug solution or acid water.
 After taking a final blood sample at 7 months, the animals 
were killed by cervical dislocation and the penis was rapidly ex-
cised from each rabbit and placed in cold oxygenated Krebs solu-
tion at 4 ° C. Tissue preparations were investigated on the same day 
of acquisition. Epidermal tissue was removed and the tunica al-
buginea opened and the corpus cavernosum dissected out and cut 
into strips of approximately 1  ! 3 mm. The size and weight for 
both control and diabetic cavernosal strips were similar.
 Organ Bath Studies 
 The strips were mounted vertically in 10-ml organ baths, 
equipped with two parallel platinum electrodes for transmural 
electrical field stimulation (EFS). The tissues were bathed with 
Krebs solution at pH 7.4, maintained at 37 ° C by a thermoregu-
lated circuit and bubbled with a mixture of 95% O2-5% CO 2 . An 
initial tension of 2 g was applied to the suspended tissue strips and 
the tension recorded on a Grass Polygraph (model 7D; Astro-med 
Grass, Slough, UK). All strips were equilibrated for at least 1 h. At 
the end of the equilibration period the strips were challenged with 
KCl (120 m M ). After washing the tissue three times, guanethidine 
(5  ! 10 –6  M ), atropine (10 –5  M ) and indomethacin (10 –6  M ) was 
added to the bathing solution and left for 20 min to inhibit the 
adrenergic, cholinergic and cyclo-oxygenase pathways, respec-
tively, leaving the NANC pathway intact. Tissues were then pre-
contracted with phenyl ephrine (10 –4  M ). The EFS of penile nerves 
were performed with a Grass S88 (Astro-med Grass, Slough UK) 
stimulator. The stimulator delivered single square waves (dura-
tion 0.8 ms; 100 V) over a range of frequencies that gave an incre-
mental increase in relaxation response (0.5–16 Hz) in 5 s trains at 
2-min intervals. A series of relaxations in response to EFS in the 
absence and presence of vardenafil (10 –8  M ) after a 20-min incu-
bation period were recorded.
 In other experiments, tissue strips were pre-contracted with 
phenylephrine (10 –4  M ) and cumulative response curves were 
constructed for SNP (3 ! 10 –9 –10 –6  M ). The tissues were then 
washed several times over a 1-hour period. Vardenafil (10 –8  M ) 
was then added to the organ bath and left for 20 min. The tissues 
were re-contracted with phenylepherine (10 –4  M ) and cumulative 
response curves were again constructed for SNP.
 The stock solution of vardenafil (10 –3  M ) was made up in acid 
water pH 4.5 and subsequently diluted in distilled water, before 
adding to the organ bath. We found that the final dilution of acid 
had no effect on SNP-induced relaxation (results not included).
 Statistical Analysis 
 Results were analysed using Graph Pad Prism 3.0. Isolated 
corpus cavernosal strips responses to SNP in the absence or pres-
ence of vardenafil are expressed as % relaxation of PE-induced 
tone. Results for the SNP (10–13 separate strips/experiment) and 
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EFS (7–12 separate strips/experiment) were obtained from 4 ani-
mals in each experimental group. Comparisons of the cumulative 
dose response curves obtained were made using analysis of vari-
ance  (2-way  ANOVA)  with  statistical  significance  accepted  at  
p  ! 0.05 (see ‘Results’). The EC 50 value recorded expressed the 
concentration of SNP required to elicit 50% of the maximum 
 relaxation of cavernosal strips (see ‘Results’).  * ,  j denotes each 
data points where there was a significant difference in SNP-medi-
ated relaxation or EFS responses between experimental groups 
( fig. 1–3 ). Statistical analysis of these data points have been deter-
mined using a Student’s unpaired or paired t test with statistical 
significance accepted at p  ! 0.05 (see figure legends).
 Results for clinical biochemical variables are expressed as 
mean  8 SD and statistical comparison between control and dia-
betic animals were determined using the Student’s unpaired t test, 
values were considered significant at p  ! 0.05.
 Results 
 Blood samples analysed after 6 months of diabetes re-
vealed a significant increase in serum glucose, creatinine 
and urea concentrations with a significant fall in serum 
sodium concentration ( table 1 ). The analysis of the 7-
month blood sample collected after in vivo vardenafil or 
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 Fig. 1. SNP-induced relaxations of cavernosal strips taken from 
control ( $ ) and diabetic rabbits (S) following vehicle treatment. 
 j Data points where there was a significant difference in SNP-in-
duced relaxation between these two experimental groups (SNP 
( M ): 3  ! 10 –8 , p  ! 0.04; 10 –7 , p  ! 0.02; 3  ! 10 –7 , p  ! 0.009; 10 –6 ,
p  ! 0.04; unpaired Student’s t test). SNP-induced relaxations of 
cavernosal strips taken from diabetic rabbits following vehicle 
treatment in the absence (S) and presence (!) of in vitro varde-
nafil.  * Data points where there was a significant difference in 
SNP-induced relaxation between these two experimental groups 
(SNP ( M ): 3  ! 10 –9 , p  ! 0.007; 10 –8 , p  ! 0.0008; 3  ! 10 –8 , p  ! 
0.0006; 10 –7 , p  ! 0.0001; 3  ! 10 –7 , p  ! 0.0001; 3  ! 10 –6 , p  ! 0.02; 
paired Student’s t test). 
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 Fig. 2. SNP-induced relaxations of cavernosal strips taken from 
diabetic rabbits following in vivo vardenafil treatment in the ab-
sence ( j ) and presence (+) of in vitro vardenafil.  * Data points 
where there was a significant difference in SNP-induced relax-
ation between the two experimental groups (SNP ( M ): 3  ! 10 –9 , 
p  ! 0.03; 10 –8 , p  ! 0.002; 3  ! 10 –8 , p  ! 0.002; 10 –7 , p  ! 0.0008;
3  ! 10 –7 , p  ! 0.002; 3  ! 10 –6 , p  ! 0.003; paired Student’s t test). 
Also presented is the SNP-induced relaxation of cavernosal strips 
taken from vehicle-treated diabetic (S) rabbits for comparison. 
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 Fig. 3. EFS-induced relaxations of cavernosal strips taken from 
diabetic rabbits following in vivo vardenafil treatment in the ab-
sence ( S ) and presence (d) of in vitro vardenafil.  * Data points 
where there was a significant difference in EFS-induced relax-
ation between the two experimental groups (EFS (Hz): 2.0, p  ! 
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vehicle treatment for 4 weeks, showed similar results to 
the 6-month sample for serum glucose, urea and sodium 
concentrations (results not shown).
 SNP-Induced Cavernosal Smooth Muscle Relaxation 
 (a) SNP-induced relaxation of diabetic cavernosal 
strips taken from animals given the vehicle was signifi-
cantly (ANOVA; p  ! 0.0001) impaired when compared 
with controls ( fig. 1 ). The EC 50 value which represents the 
concentration of SNP required to elicit 50% of the maxi-
mum relaxation was significantly increased following di-
abetes. Thus, the EC 50 value for the control strips was 7.9 
 ! 10 –8  M and the diabetic strips 3  ! 10 –7  M ; p  ! 0.01. The 
in vitro addition of vardenafil (10 –8  M ) significantly 
(ANOVA; p  ! 0.0001) enhanced the relaxation of strips 
taken from diabetic vehicle-treated animals ( fig. 1 ). The 
EC 50 values in the absence and presence of vardenafil 
were 3  ! 10 –7  M and 4.4  ! 10 –8  M ; p  ! 0.0007, respec-
tively. Interestingly, the vardenafil-induced SNP relax-
ation of diabetic cavernosal strips was greater than that 
achieved by control strips (ANOVA; p = 0.0013) ( fig. 1 ).
 (b) The in vitro addition of vardenafil (10 –8  M ) signif-
icantly (ANOVA; p  ! 0.0001: results not shown) enhanced 
the relaxation of strips taken from control vehicle-treated 
animals. The EC 50 values in the absence and presence of 
vardenafil were 7.9  ! 10 –8  M and 1.2  ! 10 –8  M ; p  ! 0.0003, 
respectively.
 (c) The cumulative response curve for cavernosal 
strips taken from diabetic animals given in vivo vardena-
fil showed a significant (ANOVA; p = 0.0004) increase in 
cavernosal relaxation when compared with untreated di-
abetic rabbits ( fig. 2 ). The EC 50 value for the non-treated 
diabetic rabbits cavernosal strips was 3  ! 10 –7  M and for 
diabetic in vivo vardenafil-treated rabbits 1.1  ! 10 –7  M .
 The in vitro addition of vardenafil (10 –8  M ) signifi-
cantly (ANOVA; p  ! 0.0001) enhanced the relaxation of 
strips taken from diabetic animals given in vivo vardena-
fil ( fig. 2 ). The EC 50 value of strips taken from diabetic 
animals given in vivo vardenafil was 1.1  ! 10 –7  M and 
3  ! 10 –8  M ; p  ! 0.02, in the absence and presence of in 
vitro vardenafil, respectively. The cavernosal relaxation 
caused by the combination of in vitro and in vivo varde-
nafil was significantly (ANOVA; p  ! 0.0001) greater than 
in vivo but not in vitro vardenafil alone ( fig. 2 ).
 Electrical Field Stimulation (EFS) 
 (d) There was an impairment of EFS-induced relax-
ation of cavernosal strips taken from vehicle-treated dia-
betic animals compared with controls (ANOVA; p = 
0.0077: results not shown).
 (e) There was no evidence that in vitro or in vivo var-
denafil alone enhanced EFS-induced relaxation of caver-
nosal strips taken from diabetic rabbits (results not 
shown).
 In contrast, the in vitro addition of vardenafil signifi-
cantly enhanced EFS-induced relaxation of strips taken 
from diabetic rabbits given in vivo vardenafil (ANOVA; 
p = 0.0026) ( fig. 3 ).
 Discussion 
 Serum clinical biochemical analysis showed that diabe-
tes was evident 1 week after the alloxan injection and was 
maintained for the duration of the study. Organ bath stud-
ies revealed that pre-contracted cavernosal strips taken 
from diabetic vehicle-treated rabbits exhibited impaired 
SNP-induced relaxation. Interestingly, diabetes-induced 
impairment of corpus cavernosal relaxation is known to 
have a deleterious effect on the erectile process  [10] and 
probably explains why the incidence of ED is as high as 
70% in diabetic men  [8, 9] and these patients are some 
times referred to as a ‘difficult-to-treat’ ED group  [20] .
 The release of NO by the endothelium of the arteries 
that supply the penis and the corpus cavernosum, as well 
as NANC neurotransmission, plays a crucial role in pe-
nile erection  [3–5] . It is also recognized that a decrease in 
NO production is a contributing factor in the develop-
ment of diabetic ED. For example, an impairment in mat-
ing and erectile reflexes, as well as a decrease in basal and 
stimulated NO levels in the corpora, together with a re-
duction in the intracavernosal pressure in response to 
cavernous nerve stimulation have been reported in dia-
betic rats  [21] . This is supported by the finding that ni-
trergic relaxation responses in vitro and erectile respons-
es to cavernous nerve stimulation in vivo were attenuated 
in a similar animal model  [22] . The reduction in NO was 
associated with a fall in penile NOS activity, a phenom-
Table 1. Serum clinical biochemical variables from 6-month 
control and diabetic rabbits
Clinical biochem-
ical variables
Control
(n = 8)
Diabetic
(n = 8)
p value (unpaired 
Student’s t test)
Glucose, mM 7.580.4 26.284.7 <0.0001
Sodium, mM 14381.1 13183.5 0.0001
Urea, mM 5.280.3 9.782.0 <0.0001
Creatinine, M 79.089.9 95.088.9 0.0045
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enon that has been observed in both type 1 and type 2 
diabetic rats  [23] . A reduction in cGMP/NO accumula-
tion also caused the impairment of corpus cavernosal 
smooth muscle relaxation in diabetic rabbits  [18] . Impor-
tantly, this impairment of smooth muscle relaxation was 
due to a decrease in NO bioavailability rather than an in-
herent inability of the corpus cavernosum to relax, since 
the sensitivity of corpus cavernosal tissue to exogenous 
NO was enhanced in diabetic rabbits  [24] . The diabetes-
induced reduction in NO could be due to a defect in NO 
synthesis and thus NANC neurotransmission or quench-
ing of NO through the production of superoxide radicals 
and advanced glycation end products  [25, 26] .
 In the present study the in vitro addition of vardenafil 
(a PDE-5 inhibitor) significantly improved the relaxation 
of corpus cavernosal strips taken from diabetic vehicle-
treated rabbits ( fig. 1 ). Vardenafil is a member of a family 
of PDE-5 inhibitors, which include sildenafil and tadala-
fil that reduce the degradation of cGMP thus enhancing 
cavernosal smooth muscle relaxation  [16, 18] , which has 
given them widespread use in the treatment of ED  [15–
17] . The present findings are consistent with our previous 
study, which found that sildenafil enhanced SNP-induced 
CSMR as well as the accumulation of cGMP in diabetic 
rabbits  [18] . This is probably due to the dissociation of 
SNP in solution generating NO, which in turn activates 
guanylyl cyclase, the enzyme that causes the production 
of cGMP. One possibility is that diabetes impairs the ac-
tivity of this enzyme, resulting in the reduction of cGMP 
formation.
 The effect of in vitro vardenafil on corpus cavernosal 
strips taken from vehicle-treated diabetic animals was 
marked, since the EC 50  value showed a 10-fold decrease 
in the concentration of SNP required to elicit 50% of the 
maximum relaxation ( fig. 1 ).
 Moreover, the SNP-mediated relaxation of diabetic 
corpus cavernosal tissue following in vitro vardenafil was 
significantly greater than that achieved by SNP on con-
trol tissue, as shown by the EC 50 values and ANOVA 
analysis. Interestingly, in vitro vardenafil also signifi-
cantly enhanced the relaxation of corpus cavernosal 
strips taken from vehicle-treated control animals (results 
not shown). These findings taken together confirm that 
vardenafil is a potent and highly selective PDE-5 inhibi-
tor. This is supported by the finding that vardenafil is 
more potent and selective than sildenafil at inhibiting 
phosphodiesterase-5  [7] . It is also more effective than 
sildenafil in facilitating erections in anaesthetized rabbits 
 [27] and relaxing pre-contracted bladder, prostate and 
urethral tissue taken from rats  [19] .
 Diabetic rabbits receiving in vivo vardenafil showed 
an enhancement in SNP-induced relaxation of caverno-
sal strips compared with untreated diabetic animals. This 
enhanced cavernosal relaxation after in vivo vardenafil 
was augmented by in vitro vardenafil ( fig. 2 ). The im-
provement of corpus cavernosal relaxation following the 
combination of in vitro and in vivo vardenafil provides 
further evidence of its potent and selective PDE-5 inhib-
itory capacity.
 EFS-mediated corpus cavernosal relaxations were sig-
nificantly impaired in vehicle-treated diabetic animals 
compared with controls (results not shown), which is in 
keeping with the development of diabetic ED.
 We previously found that impaired EFS-mediated re-
laxation was evident after 6 months diabetes but not after 
3 months. In contrast, impaired SNP-induced relaxation 
of cavernosal strips was evident after 3 months diabetes 
 [18] .
 This discrepancy between the development of im-
paired SNP and EFS-induced diabetic cavernosal relax-
ation might reflect the time course of the deleterious ef-
fects of diabetes on penile function. It would suggest that 
disruption of endothelium function is probably an early 
event (impaired SNP-induced relaxations seen at 3 
months), followed by the later impairment of the NANC 
pathway (impaired EFS-induced relaxations seen at 6 
months). It is possible that at 6 months diabetic neuropa-
thy may have developed. There is biochemical evidence to 
support the development of diabetic neuropathy in this 
model, since early signs of vascular neuropathy, charac-
terised by a reduction in the neuronal content and release 
of noradrenaline by sympathetic nerves is evident in 6-
week diabetic rabbits  [28] . It is conceivable that the bio-
chemical changes could in time cause some degree of neu-
ropathy, leading to the impairment of the NANC pathway, 
contributing to the development of ED. Clinical evidence 
of possible diabetes-induced neuropathy is provided by 
the finding that impotence in diabetic men was secondary 
to a neuropathic change to cholinergic nerves in the cor-
pus cavernosum  [29] . It has also been reported that EFS-
induced relaxations were impaired in corpus cavernosal 
tissue taken from diabetic patients with ED  [10] .
 In the present study, EFS-induced relaxations were en-
hanced when vardenafil was added in vitro to cavernosal 
tissue taken from diabetic rabbits receiving in vivo var-
denafil ( fig. 3 ). This finding, together with the in vivo ef-
fect of vardenafil on SNP-induced diabetic corpus caver-
nosal relaxation ( fig. 2 ), may have clinical significance.
 Neuropraxia caused by nerve damage is thought to be 
a contributing factor for post-operative ED following 
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nerve-sparing radical prostatectomy, which can lead to 
poor corporeal oxygenation, facilitating corporeal fibro-
sis and veno-occlusive dysfunction  [30] .
 Although PDE-5 inhibitors can be used to treat post-
prostatectomy ED  [31,32] , their use as a prophylaxis has 
not been fully elucidated. It is thought, however, that tak-
ing these drugs at bedtime might facilitate nocturnal 
erections, giving some protection for corpus cavernosal 
baseline function  [30] .
 Thus, in giving diabetic rabbits in vivo vardenafil we 
may be providing corpus cavernosal endothelium protec-
tion that is evident with/without in vitro vardenafil for 
SNP-mediated relaxations. On the other hand, the neu-
ronal protection might be reduced because of the devel-
opment of diabetic neuropathy, which might explain why 
EFS-mediated cavernosal relaxations were not enhanced 
by in vitro or in vivo vardenafil alone but only by the 
combination of both. This suggests that the combined 
treatment carried out in our experiment compensated for 
the impaired diabetic NANC drive.
 The effectiveness of in vivo vardenafil was indepen-
dent of glycaemic control since diabetic serum glucose 
concentration was similar before and after treatment. 
This is in agreement with clinical evidence that shows the 
dose-dependent benefit of vardenafil in diabetic ED  [20] 
seems  to  occur  regardless  of the level of glycaemic con-
trol  [9] .
 In conclusion, the present findings suggest that the 
functional response of the corpus cavernosal tissue of di-
abetic rabbits to NO is intact (i.e. an enhanced SNP-me-
diated relaxation of diabetic cavernosal tissue following 
in vitro and in vivo vardenafil treatment). In contrast, the 
failure of in vitro and in vivo vardenafil to elicit an in-
crease in EFS-mediated relaxation suggests that there is a 
defect in the NANC drive, which is probably a reflection 
of diabetic neuropathy. The combination of in vitro and 
in vivo vardenafil compensated for the reduced NANC 
drive. These observations reinforce the use of vardenafil 
in the treatment of diabetic ED.
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Introduction
Purinergic signalling and purinergic neuro-transmission
was first proposed over 30 years ago (Burnstock, 2002).
Purine nucleotides are extra-cellular messengers, which
act on either P1 or P2 receptors (Burnstock, 2002; Ab-
bracchio et al., 2003). P1 receptors are coupled to G-pro-
teins and subdivided into A1, A2A, A2B and A3 receptor
subtypes. P2 receptors are subdivided into P2X(1–7) and
P2Y(1,2,4,6,11,12,13,14) receptor subtypes. P2X receptors are
ligand-gated ion channels whereas P2Y receptors are cou-
pled to G-proteins. Activation of P1 and P2 receptors
mediate many cellular functions including neurotransmis-
sion, cell proliferation and death (Burnstock, 2002). In
the urinary tract purinergic signalling is implicated in the
regulation of renin secretion and glomerular filtration in
the kidney (Jackson, 2005) and afferent sensations such as
pain and distension in the bladder and also neurogenic
contraction of the bladder smooth muscle (Hashimoto &
Kokubun, 1995; Burnstock, 2001). In penis, P2Y1 receptor
is expressed in endothelial cells which lines the lacunar
space and blood vessels, but not expressed in corpus cav-
ernosum smooth muscle cells and urethra (Obara et al.,
1998).
Previous studies provide evidence of the possible puri-
nergic involvement in the erectile process. For example,
adenosine has been shown to induce cavernosal smooth
muscle (CSM) relaxation (Wu et al., 1993; Chiang et al.,
1994; Mantelli et al., 1995; Ragazzi et al., 1996), increase
cavernosal peak blood flow velocity (Filippi et al., 2000)
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Summary
The activation of P2Y6 receptors has been previously reported to cause vascular
smooth muscle constriction and relaxation. The aim of our study was to deter-
mine the effect of P2Y6 receptor subtype activation on human cavernosal func-
tion. Cavernosal tissue was obtained from 23 patients undergoing gender
reassignment surgery. Immunohistochemistry (IHC) and Western blotting were
used to determine the presence of P2Y6 receptors in corpus cavernosal tissue.
The effects of UDP (a selective P2Y6 receptor agonist) before and after the
addition of distilled water (control), cibacron blue 3GA (CB, a P2Y6 receptor
antagonist; 10)4 m) or N-nitro-l-arginine methyl esther (l-NAME, a NO syn-
thase inhibitor; 10)4 m) were assessed on phenylephrine (PE; 10)4 m) pre-con-
tracted cavernosal strips using organ baths. Electrical field stimulation (EFS;
0.5–32 Hz) was performed in the absence and presence of CB to determine
neuronal-mediated P2Y6 receptor responses. IHC and Western blotting revealed
the presence of P2Y6 receptors on cavernosal sections. UDP at 10
)4 m and
10)3 m induced a 5% and 16% relaxation of the PE-mediated response (both
p < 0.0001), respectively, which was significantly blocked by CB (48% reduc-
tion of the UDP 10)3 m response, p < 0.002) but not affected by l-NAME.
EFS-induced relaxations of pre-contraction strips were not significantly altered
by CB. We have found the presence of P2Y6 receptors in human cavernosal tis-
sues, that when activated induce cavernosal smooth muscle cell relaxation via
non-neuronal and non-nitric oxide dependent mechanism. Further investiga-
tion is needed to establish whether P2Y6 receptors play a physiological role in
penile erection.
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and penile tumescence (Noto et al., 2001). The adenosine-
mediated relaxation of CSM was shown to act via A2A
(pathway independent of nitric oxide, NO) (Mantelli et al.,
1995) and A2B (partially endothelium-dependent) (Chiang
et al., 1994) receptor subtypes.
Adenosine 5¢-triphosphate (ATP) released neuronally
(Burnstock, 2002) or possibly derived from the endothe-
lium [based on the hypothesis for purinergic mechano-
sensory tranduction in tissues such as the bladder as
described by Burnstock (Burnstock, 2002)], has also been
shown to induce CSM relaxation (Tong et al., 1992; Wu
et al., 1993; Levin et al., 1994, 1995; Ragazzi et al., 1996;
Filippi et al., 1999; Noto et al., 2001). The effect of ATP
on CSM-induced relaxation could be due, in part, to its
metabolic breakdown to adenosine, which acts directly on
the CSM A2A receptor subtype (Filippi et al., 1999). Inter-
estingly, ATP-mediated relaxation is more pronounced
when the CSM has a high-basal tension (following pre-
stimulation with phenylephrine (PE) (Wu et al., 1993),
akin to normal physiological basal tone). It may be that
ATP forms part of a regulatory mechanism that maintains
physiological CSM basal tone.
Although previous studies have indicated that the acti-
vation of P2Y receptors modulates CSM function (Shalev
et al., 1999; Staerman et al., 2000), the activation of P2Y6
receptors in vascular tissue has yielded conflicting results.
Malmsjo et al. (2000) found that stimulation of P2Y1,2,4
receptors led to relaxation of the rat-isolated mesenteric
artery, while activation of P2Y6 receptors caused vasocon-
striction. In contrast, Guns et al. (2006) found that stim-
ulation of P2Y6 receptor by UDP led to relaxation of the
mouse isolated thoracic aorta. This difference could
reflect species variation. However, as the CSM is akin to
a modified vascular tissue, it is important to determine
whether P2Y6 receptors are present in human CSM and if
the activation of the receptor induces smooth muscle
constriction or relaxation. Thus, the aim of this study was
to establish the presence and functional response of P2Y6
receptors in human cavernosal tissue. The results from
this study may have important implications in the modu-
lation of the erectile process.
Material and methods
Tissue
Human penile organs were obtained from 23 male patients
undergoing gender reassignment surgery (male to female)
at Charing Cross hospital, London, UK (mean age 30 years,
range 23–57 years). Approval was obtained from the River-
side Ethics Committee, London, UK and all the patients
gave their informed consent prior to surgery. All patients
had no history of previous illness (including diabetes)
and were not on any medication apart from oestrogen
supplement for at least 2 years prior to surgery. Oestrogen
therapy was discontinued 2 months prior to surgery.
Immunohistochemistry
For tissue immunohistochemistry (IHC), the human cav-
ernosal tissue sections were fixed in 4% neutral buffered
formaldehyde for 24 h and then embedded in paraffin.
After hematoxylin and eosin (H&E) staining the sections
were examined to confirm tissue type (Fig. 1a). Paraffin
sections (3 lm) of the cavernosal tissue sections were then
deparaffinized and rehydrated, and for antigen retrieval,
they were incubated with citrate buffer (10 mm, pH 6.0)
and heated twice in a microwave oven at 750 watts for
5 min. The sections were incubated with primary
polyclonal anti-P2Y6 antibody (Alomone Laboratories,
Jerusalem, Israel). The antibody was titrated prior to stain-
ing to obtain an optimal dilution producing crisp staining
with minimum background. The sections were incubated
with the primary antibody at a dilution of 1 : 200 for 24 h
at 4 C. After washing three times with posphate-buffered
saline (PBS), the sections were incubated with biotinylated
secondary antibody against goat IgG (Goat anti-rabbit
immunoglobulin – biotinylated, Stratech Scientific Ltd,
Suffolk, UK). The sections were kept for 45 min at room
temperature and then washed three times with PBS. This
was followed by the addition of the Avidin–Biotin complex
for 45 min followed by a repeat series of washes with PBS.
DAB (3,3¢-diaminobenzidin tetrahydrochloride reagent
as included in the DAKO ChemMateTM kit, DAKO Ltd,
Cambridgeshire, UK) was then added to the sections for
approximately 10 min. The tissue sections were counter
stained with haematoxylin, dehydrated, cleared and
mounted in Pertex and viewed under light microscopy.
Negative controls were performed by omitting the
primary antibody in the steps described above. Positive
controls were also performed on rat brain tissue, where it
is known that P2Y6 receptors are abundant.
Western blotting
Protein extraction
Cavernosa tissues were snap frozen in liquid nitrogen and
stored at )70 C. Proteins were extracted from the sam-
ples using a ratio of 1 mL of lysis buffer (50 mm TRIS
base and 50 mm NaCl; PH 7.4 with 1% w ⁄ v SDS) per
300 lg sample. Protease inhibitors were added (leupeptin
1 l ⁄mL, chymostatin 10 lg ⁄mL, bestatin 40 l ⁄mL, pepst-
atin A 1 l ⁄mL, N-a-p-tosyl-l-lysine chloromethyl ketone
50 lg ⁄mL) to inhibit NOS proteolysis. Protein concentra-
tion was determined using a microplate DC Protein Assay
Kit (Bio-Rad Laboratories, Hemel Hempstead, UK). The
absorbance was read at 750 nm against a protein standard
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curve generated using bovine serum albumin (0.2–
10 mg ⁄mL).
Western blot analysis
Protein was combined with an equal volume of loading
buffer [0.5 m Tris–HCL (PH 6.8), 20% w ⁄ v glycerol 10%
w ⁄ v SDS, 0.1 m DL-dithiothrietol and 0.05% w ⁄ v brom-
ophenol blue] and denatured by boiling for 10 min.
Samples were electrophoresed through a 7.5% w ⁄ v SDS-
polyacrylamide gel and transferred to a 0.45 lm-nitrocellu-
lose membrane (Schleicher, Dassel, Germany). Membranes
were immersed in blocking solution containing 5% w ⁄ v
non-fat dry milk before incubation with P2Y6 receptor
antibodies in TRIS – buffer saline with 0.15% w ⁄ v Tween-
20 (TBS-T). After 2 h incubation at room temperature,
membranes were washed for 1 · 15 min, followed by
3 · 5 min in TBS-T and then incubated for 1 h with goat
anti-rabbit antisera conjugated with hourseradish peroxi-
dase 1 : 13 000 with TBS-T. The protein was detected using
an ECLTM – chemiluminescence detection Kit (Amersham,
Little Chalfont, UK). Rat brain tissue lysates for P2Y6
receptor was used as a positive control.
Organ bath studies
Isolated human cavernosal tissues were cut into strips of
approximately 2 · 5 mm length. The strips were mounted
vertically in 10 mL organ baths containing Krebs solution.
The Krebs solution (pH 7.2) had the following composi-
tion (mm): NaCl 133, KCl 4.7, NaH2PO4 1.35, NaHCO3
16.3, MgSO4 0.61, CaCl2 2.52 and glucose 7.8. The tissue
strips were maintained at 37±1 C and bubbled with
a mixture of 95% O2 and 5% CO2. An initial tension of
2 g was applied and the strips were allowed to equilibrate
for 1 h before being challenged with KCl (124 m), which
was repeated at the end of the experiment. Results were
only accepted if both KCl responses varied in magnitude
by <10%.
Initial experiments showed that UDP (a selective
P2Y6 receptor agonist) caused cavernosal relaxations.
(a) (b)
(c) (d)
Figure 1 Four cavernosal sections are shown;
(a) stained with hematoxylin and eosin, (b)
immunohistochemical staining with a P2Y6
receptor antibody, (c) immunohistochemical
staining following omission of the P2Y6 recep-
tor antibody (negative control) and (d) immu-
nohistochemical staining with a P2Y6 receptor
antibody on sections of rat brain, which is
known to have P2Y6 receptors (positive con-
trol) (n = 6).
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Subsequently, all tissues were pre-contracted with PE
10)4 m to quantify UDP-induced relaxations at a concen-
tration of 10)3 m and 10)4 m, (n = 9 for each concentra-
tion). In some experiments, cibacron blue 3GA (CB, a
P2Y6 receptor antagonist; 10
)4 m, n = 9) or N-nitro-l-
arginine methyl esther (l-NAME; a NO synthase inhibi-
tor; 10)4 m, n = 9) was added to the strips and kept for
20 min prior to re-exposure to UDP 10)3 m.
In other experiments, strips were exposed to atropine
10)5 m, guanethidine 5 · 10)6 m and indomethacin
10)6 m for 20 min to inhibit the parasympathetic, sympa-
thetic and prostaglandin pathways, respectively. Electrical
field stimulations (EFS) at 100 V and 0.1 ms (5 sec dura-
tion and a 2 min rest interval) at a frequency of
0.5–32 Hz were then performed on PE pre-contracted
cavernosal strips before and after the addition of CB
10)4 m.
Control experiments were also performed examining
the effect of distilled water (vehicle) on the UDP-induced
relaxation on PE pre-contracted strips.
Chemicals
Phenylephrine, UDP, CB and KCl were supplied by Sigma
Chemical Co. (Poole, UK).
Statistical analysis
Isolated cavernosal strips responses to UDP before and
after pre-incubation with either CB, l-NAME or distilled
water is expressed as mean values ± SEM, comparisons
were made using Student paired t-test. Individual EFS
stimulation points (expressed as mean values ± SEM)
where compared before and after the addition of CB
using Student paired t-test. Results from both series of
experiments are expressed as a percentage of the PE
response and significance was considered at p < 0.05.
The comparison of EFS curves was performed using
anova analysis, with statistical significance accepted with
p < 0.05.
Results
Immunohistochemistry
Sequential tissue sections underwent one of two staining
techniques: H&E staining identified cellular structure
(nuclei and cytoplasm) (Fig. 1a), IHC of the P2Y6
receptor antibody showed positive brown staining for the
P2Y6 receptor on the corpus CSM cells. No staining was
demonstrated on endothelial cells of lacunar spaces and
blood vessels (Fig. 1b), the negative control section
showed no IHC staining following omission of the pri-
mary antibody (Fig. 1c). Positive control sections showed
brown staining of the P2Y6 receptor on rat brain cells
(Fig. 1d).
Western blotting
Western blotting demonstrated the presence of a band at
45 kDa, which corresponds to the P2Y6 receptor protein
in cavernosal tissue (Fig. 2).
Organ bath studies
UDP caused a significant and sustained relaxation of PE
pre-contracted tissue at both concentrations used
(10)4 m, 4.9 ± 0.8; 10)3 m, 15.7 ± 2.8, both p < 0.0001)
when compared with controls. The UDP-mediated relaxa-
tion (10)3 m) was significantly reduced by CB (8.2 ± 1.5,
p < 0.002). Whilst in contrast, l-NAME had no signifi-
cant effect on UDP-mediated relaxations (10)3 m,
17.1 ± 4.4) (Fig. 3). EFS (0.5–32 Hz) demonstrated tran-
sient relaxations on PE pre-contracted tissue strips with
maximal relaxation of 32.8 ± 4.9 at 8 Hz. EFS-induced
relaxations were not significantly altered by pre-exposure
to CB when the relaxation curves (Fig. 4) or individual
points were compared.
Discussion
We have shown for the first time, the presence of the
P2Y6 receptor subtype in human CSM using IHC and
Western Blotting. The P2Y6 receptor antibody used has
been previously shown to act specifically on P2Y6 recep-
tors (Pinna et al., 2005; Metcalfe et al., 2007). In addition,
organ bath studies revealed that activation of these recep-
tors causes a significant receptor-mediated relaxation of
human CSM. This was demonstrated by UDP (10)4 m
and 10)3 m) a compound known to act selectively on
P2Y6 receptor (Rubino et al., 1999; Metcalfe et al., 2007)
Figure 2 Western blotting gel electrophoresis shows a positive control (P2Y6 receptor protein of rat brain tissue lysates; denoted by +ve) and the
presence of the 45 kDa protein of the P2Y6 receptor in cavernosal muscle (denoted by P2Y6; two samples are shown). The negative control was
demonstrated by omitting the P2Y6 receptor protein antibody (denoted by –ve). A kDa ladder for the protein is also shown (n = 6).
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inducing a 5% and 16% relaxation of the PE-mediated
response, respectively, which was significantly blocked by
CB 10)4 m (48% reduction of the UDP 10)3 m response).
Our findings are in agreement with an earlier study,
which showed that UDP causes vasorelaxation of the
mouse thoracic aorta (Guns et al., 2006). However, our
study raises the question of whether the low % relaxation
(5% and 16%) induced by UDP, albeit significant, has
any physiological importance. No doubt more studies are
required to answer this question. It may be that the acti-
vation of P2Y6 receptors plays a role in ‘fine tuning’ the
modulation of penile erection in what appears to be
a complex process at the molecular level.
The notion that P2Y receptor activation induces
endothelium-dependent relaxation of human CSM, via
NO production is plausible (Staerman et al., 2000) as NO
plays a significant role in modulating human CSM relaxa-
tion and therefore erectile function (Burnett, 2004; Gha-
layini, 2004; Gonzalez-Cadavid & Rajfer, 2004). Equally
plausible is that the release of purines from the penile
nerve or endothelium (possibly because of CSM stretch-
ing during tumescence) could stimulate the P2Y6 recep-
tors on the CSM or endothelium causing relaxation,
a phenomenon that has been seen in the bladder (Sun &
Chai, 2006). These are, however, unlikely scenarios as the
addition of l-NAME, the nitric oxide synthase inhibitor,
had no effect on UDP-induced relaxations of PE pre-con-
tracted human CSM, ruling out the involvement of the
nitrergenic pathway in this response. l-NAME is used
widely to inhibit endogenous NO bioactivity of various
organ systems (Reilly et al., 1997; Takimoto et al., 2005;
Badn et al., 2007; Wainwright et al., 2007). In addition,
CB, the P2Y6 receptor antagonist, had no effect on EFS-
induced relaxations of PE pre-contracted human CSM,
ruling out the activation of a P2Y6-mediated neuronal
pathway.
The non-availability of normal human corpus caverno-
sum (HCC) is an unavoidable limitation of this study. In
previous studies, HCC tissues were obtained from patients
with Peyronie’s disease, diabetes or undergoing penile
prosthesis implants for erectile dysfunction (ED) (Mirone
et al., 2000), all these samples had some degree of patho-
logy. Mirone et al. (2000) and Rees et al. (2001) proposed
the use of HCC tissue obtained from patients undergoing
gender reassignment surgery. However, these patients are
normally on oestrogen for 2 years prior to withdrawal for
2 months before surgery. We, therefore, cannot exclude
the effect of oestrogen on cavernosal tissue function. In
fact, Adaikan & Srilatha (2003) showed that oestrogen
causes pathophysiological changes in the erectile function
of male rats. We did find, however, in a previous study,
that one patient who had never received oestrogen
therapy, had similar 5-HT-induced contractions to those
patients on oestrogen (Lau et al., 2006). In addition, many
gender-reassigned patients who stop taking oestrogen,
prior to surgery have ‘normal’ erections (indicated by
the presence of early morning erections) based on clini-
cal interviews, suggesting that the effect of oestrogen is
reversible (Lau et al., 2006).
Understanding the role the purinergic pathway might
play in the erectile process is important, as this informa-
tion would increase our knowledge of the mediators
involved in the pathophysiology of erectile dysfunction.
Erectile dysfunction is a known complication of diabetes
mellitus (Sullivan et al., 1999; Gur & Ozturk, 2000; Jack-
son, 2004) because of impaired relaxation of CSM (Gur
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Figure 4 Figure shows the electrical field stimulation (EFS)-induced
relaxations in the absence and presence of cibacron blue 3GA 10)4 M
(CB, a P2Y6 receptor antagonist) (n = 9).
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Figure 3 Bar diagram represents the UDP (a P2Y6 receptor agonist)-
mediated relaxations (10)4 M and 10)3 M) on phenylephrine (PE) pre-
contracted human cavernosal strips. The UDP-mediated relaxations
(10)3 M) were also determined on the PE pre-contracted tissue strips
in the presence of N-nitro-l-arginine methyl esther (l-NAME) 10)4 M or
cibacron blue 3GA 10)4 M (CB, a P2Y6 receptor antagonist). Control
experiments were performed by the addition of distilled water (DH20),
the vehicle for l-NAME, UDP, PE and CB on the PE pre-contracted
tissue strips. Relaxations are expressed as % of PE-mediated responses
(mean ± standard error of means). Significance of result is denoted by
*p < 0.002 or **p < 0.0001 (n = 20).
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& Ozturk, 2000). Interestingly, adenosine and ATP are
known to induce relaxation of CSM taken from diabetic
(Gur & Ozturk, 2000). This would suggest that alteration
in the purinergic system might be involved in the patho-
genesis of diabetes-related erectile dysfunction.
Chiang et al. (1994) demonstrated that the combina-
tion of adenosine and prostaglandin (PGE1) is more
effective than PGE1 alone in promoting erection in
humans. Targeting the purinergic pathway (for example
the P2Y6 receptor) may form a novel therapeutic option
in the treatment of erectile dysfunction, in combination
with other erectogens such as PDE5 inhibitors and
PGE1.
In conclusion, we have demonstrated that modulation
of human CSM relaxation can be achieved by activation
of the P2Y6 receptor via non-neuronal and non-NO-
dependent mechanisms, reinforcing the possible involve-
ment of purinergic signalling in the erectile process. More
work is required to determine the post-receptor mecha-
nism(s) involved in P2Y6 receptor-mediated relaxation, as
well as, establishing whether purinergic modulation (P2Y6
receptor activation) of human CSM plays a physiological
role in penile erection.
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Abstract. Background: Diabetic nephropathy is a common
cause of impaired renal function. We investigated the effect
vardenafil, a phosphodiesterase type 5 (PDE-5) inhibitor, has
on renal function in the diabetic rabbit. Materials and
Methods: Blood was taken at 4 and 6 months from control
and alloxan-induced diabetic animals (n=8, in each group)
and biochemical variables pertaining to renal function
determined. A 7-month sample was also analysed after giving
control and diabetic animals (n=4 in each group) either
vardenafil (3 mg/kg) or vehicle to drink for 4 weeks. Spot urine
total protein/ creatinine ratio (TP/C) was determined at 4 and
6 months. At 7 months a 24 h-urine sample was collected to
measure TP/C and creatinine clearance (CrCl). Results: There
was a significant increase in serum creatinine concentration
after 6 months diabetes, which was significantly reduced by
vardenafil. TP/C from diabetic rabbit spot urine samples at 6
months were significantly elevated compared to control
animals, indicating the presence of proteinuria. Vardenafil
treatment caused a normalisation of TP/C. Diabetic animals
receiving vardenafil showed a significant improvement in CrCl
when compared with diabetic animals given vehicle.
Conclusion: These findings highlight a potential role for
vardenafil in the treatment of diabetic nephropathy.
Chronic kidney disease is increasing worldwide at an annual
rate of 8%, with the prevalence higher in developing
countries than in the developed world (1). Diabetic
nephropathy is one of the most common causes of this
problem (1). In fact it is the commonest cause of end stage
renal failure in many countries and is associated not only
with a high morbidity rate but also an increase in mortality
(2-5). It can affect 20-30% of the diabetic population and
presents in its earliest stage with an increased excretion of
albumin (microalbuminuria) in the urine (4). There is also
evidence of an increase in systemic and vascular markers of
inflammation (6), with the progressive growth of the kidney
(7). Accompanying these changes are abnormalities in the
blood biochemical indices of renal function, which precede
renal failure (8). 
The primary treatment of diabetic nephropathy has
focused on the integrated targeting of glycaemic and blood
pressure control to reduce microalbuminuria (3, 9, 10). 
Some patients, however, progress to end stage renal
disease and require renal replacement therapy. It has been
estimated that this treatment can cost as much as 40,000-
50,000 Euros /patient each year (5). Not surprisingly, with
the increasing number of diabetics on renal replacement
therapy a financial strain is placed on health care systems
(2). Thus, the need to develop new treatment strategies for
diabetic nephropathy is obvious.
In the present study, we investigate the effect oral
vardenafil, a phosphodiesterase type 5 (PDE-5) inhibitor,
has on diabetic renal function.
Materials and Methods
Induction of diabetes. Adult mature male rabbits (n=8), fed ad
libitum, were injected intravenously with alloxan (65 mg/kg made
up in 1 ml/kg, saline), while 8 control animals were injected with
the saline vehicle alone (1 ml/kg), after a blood sample was taken.
Diabetic animals received 3 subcutaneous injections of 10 ml of
50% glucose, 4 h apart on the first day of alloxan treatment. A final
glucose injection (10 ml of a 50% glucose solution) was
administered on the morning (7. 30 am) of the second day. This
procedure was carried out to counteract the hypoglycaemia caused
by insulin release from necrosed pancreatic beta cells due to the
acute action of alloxan.
Within 1 week of the alloxan injection, blood samples not
exceeding more than 10% of the total blood volume were taken to
confirm diabetes. Thereafter, blood samples not exceeding 15% of
the total blood volume were taken at 4 and 6 months to monitor
serum biochemical variables that directly relate to renal function
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(urea, sodium, and creatinine), as well as, glucose and bicarbonate.
Spot urine samples were also collected at 4 and 6 months from
control and diabetic animals for the measurement of total protein
and creatinine concentrations.
Experimental animal groups. After 6 months the control and
diabetic animals were divided into 4 groups.
Group 1 (4 control rabbits) and Group 2 (4 diabetic rabbits)
were given vardenafil (3 mg/kg, Bayer Healthcare AG, Germany)
made up in 120 ml HCl acid water, pH 4.5, to drink each morning
for 4 weeks, this was followed by HCl acid water, pH 4.5, given ad
libitum. Animals in Group 3 (4 control rabbits) and Group 4 (4
diabetic rabbits) received HCl acid water, pH 4.5, to drink ad
libitum for 4 weeks. The vardenafil dose used has been reported to
be the minimum necessary to elicit urological changes following
partial bladder outlet obstruction in the rat (11). 
Rabbits in all four experimental groups readily drank the
vardenafil solution or vehicle. 
The final 7-month blood sample was taken after 4 weeks
vardenafil or vehicle treatment. 
All animals were placed in metabolic cages at 7 months to
collect 24 h urine samples to measure total protein and creatinine
concentrations, as well as to determine creatinine clearance (CrCl).
Kidney sections were also collected from control and diabetic
vehicle-treated rabbits for transmission electron microscopy (TEM).
Animals were weighed at the start and the end of the study.
Statistical analysis. For parametric analysis the results are expressed
as mean±SD using a Student's unpaired or paired t-test, with
statistical significance accepted at p<0.05. For nonparametric
analysis, the results are expressed as median with range using the
Mann Whitney unpaired test and the Wilcoxon paired test. Values
from both tests were considered significant at p<0.05 
Results
The starting weights of control rabbits were less than the
diabetic rabbits [control: 3.0 (2.8 -3.2kg); diabetic: 3.3 (3.2-
3.4 kg; p=0.002) Mann Whitney test, n=8]. At the end of 7
months, the control animals were significantly (p=0.008;
Wilcoxon test) heavier than their starting weights, while the
diabetic animals showed no significant change from their
starting weights, [control: 3.9 (3.6 - 4.3kg); diabetic: 4.0 (2.2-
4.8 kg) n=8]. The final weight of the control animals was
not significantly different from the final weight of the
diabetic animals.
Serum glucose concentration was significantly elevated 1
week after the alloxan injection compared to vehicle-treated
control animals (similar to serum glucose concentration in
Table I). Acid water treatment did not induce metabolic
acidosis, since there were no significant difference in serum
bicarbonate concentration in control and diabetic animals
before and after acid water or vardenafil treatment. For
example, 6 month diabetic serum bicarbonate before
vardenafil treatment was 26 mmol/l (20-28 mmol/l, n=4); 7
month diabetic serum bicarbonate after vardenafil
treatment was 26 mmol/l (22-27 mmol/l, n=4). 
Blood samples analysed from 4-month (results not
shown) and 6-month diabetic animals (Table I) revealed
impaired renal function as there was a significant increase
in serum creatinine and urea concentrations. There was also
a significant increase in serum glucose concentration, with
a significant fall in serum sodium concentration. 
Serum creatinine (Ìmol/l) concentration from diabetic rabbits
before and after oral vardenafil treatment. The diabetes-
induced increase in serum creatinine concentration was
significantly reduced by vardenafil (6-month diabetic
creatinine: 97±13 Ìmol/l; n=4 vs. 7-month diabetic creatinine
following vardenafil: 87±12 Ìmol/l; n=4, p=0.015; paired
Student's t-test.
Urinary total protein (g/l) / creatinine (mmol/l) ratio (TP/C)
from control and diabetic rabbits with and without oral
vardenafil treatment. TP/C from diabetic rabbit urine samples
at 6 months but not at 4 months (results not shown) was
significantly elevated compared with controls, indicating the
presence of proteinuria. Control TP/C: n=8, 0.0116 (0.0091-
0.0191) vs. diabetic TP/C: n=8, 0.0227 (0.0096-0.1632),
p<0.038 (Mann Whitney, unpaired test). Vardenafil
treatment caused a normalisation of TP/C from diabetic
animals (n=3) at 0.0143 (0.0118-0.0176). 
Creatinine clearance (CrCl) following 4 weeks’ oral vardenafil
or vehicle treatment from 7-month control and diabetic rabbits.
Control rabbits receiving vehicle had a CrCl of 9.3±3.3
ml/min, a value not statistically different from control
animals receiving oral vardenafil (8.0±0.5 ml/min).
Diabetic vehicle-treated rabbits had a fall in CrCl
compared with vehicle-treated controls, however, the
difference was not statistically significant.
In contrast, diabetic animals receiving vardenafil showed
a significant improvement in CrCl compared with diabetic
animals given vehicle: diabetic vehicle-treated, 6.1±3.7
ml/min, n=4 vs. diabetic vardenafil-treated, 11.3±1.0
ml/min, n=4, p=0.035 (unpaired Student's t-test). This
improvement in CrCl was not statistically different from
in vivo 21: 851-854 (2007)
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Table I. Serum biochemical variables from 6-month control and diabetic
rabbits: evidence of renal impairment. 
Biochemical Control (n=8) Diabetes (n=8) P-value
variable mean±SD mean±SD (unpaired
Student's t-test)
Glucose (mmol/l) 7.5±0.4 26.2±4.7 <0.0001
Sodium (mmol/l) 143±1 131±4 0.0001
Urea (mmol/l) 5.2±0.3 9.7±2.0 <0.0001
Creatinine (Ìmol/l) 79.0±10 95.0±9 0.0045
control animals receiving vehicle. Similar results were found
even when CrCl was expressed per kg (results not shown).
Transmission electron microscopy (TEM) comparison of
kidney sections taken from vehicle-treated control and diabetic
rabbits. TEM revealed no significant evidence of morpho-
logical changes between control and diabetic rabbit kidney
sections following vehicle treatment. 
Discussion
The serum biochemical data presented in this study
demonstrate that significant renal impairment is evident 6
months following the induction of diabetes (a rise in serum
creatinine and urea and a fall in sodium concentrations).
We have previously reported similar findings. In addition,
we found renal impairment starts much earlier than we
report here (3 months after the induction of diabetes) (12).
The effect of vardenafil (a PDE-5 inhibitor) on the erectile
process and in particular its beneficial actions on patients
with erectile dysfunction are well-documented (13,14). 
Here, for the first time, we report that 4-week treatment
with oral vardenafil significantly reduced the diabetic-induced
increase in serum creatinine concentration. We also report
that the diabetic rabbits had an elevated urinary TP/C [a test
for proteinuria (15)], which was normalised by vardenafil.
Taken together, these findings imply that vardenafil can
reduce proteinuria and improve the renal status in diabetic
nephropathy. It appears that this property is only evident
when kidney function is impaired, since vardenafil had no
effect on the renal function of control rabbits.
The early stages of diabetic nephropathy are
characterised by an increase in glomerular hyperfiltration,
which increases the glomerular filtration rate (GFR) and is
believed to contribute to the progression of renal
impairment (7, 16). As the nephropathy progresses, renal
function deteriorates and a reduction in GFR becomes
evident (17, 18). 
In our study, we measured CrCl, an index of GFR (19),
and found that control animals had similar CrCl values to
the GFR values previously reported for control rabbits (20).
We also found that diabetic vehicle-treated animals did not
show evidence of glomerular hyperfiltration (elevated CrCl),
when compared with vehicle-treated control animals. In
fact, our data suggest that diabetic animals were moving
into the phase when GFR starts to fall and before
significant morphological changes become evident.
Interestingly, diabetic rabbits that received vardenafil
showed a significant increase in CrCl, compared with
diabetic vehicle-treated animals, providing further evidence
of drug-induced improvement in renal function.
Importantly, this increase did not induce glomerular
hyperfiltration, since CrCl was not significantly greater than
that obtained from control vehicle-treated animals. Nor was
the increase related to differences in the final body weight
of the animals in each group, since results were similar
when CrCl was expressed per kg.
A possible mechanism for the action of vardenafil on
diabetes-induced impaired renal function can be inferred
from previous studies. It has been proposed that glomerular
hyperfiltration is significantly dependent upon an increase in
nitric oxide (NO) activity in the early phase of diabetic
nephropathy (21). However, in the later phase when the GFR
starts to fall a concomitant reduction in NO activity seems to
occur. The diabetes-induced reduction in NO activity could
be due to a defect in synthesis or quenching through the
production of superoxide radicals and advanced glycosylation
end products (22, 23). In the context of renal function an
increase in NO/cGMP activity would cause renal vasodilation.
Thus, vardenafil, a potent and highly selective PDE-5
inhibitor may be restoring GFR, reducing serum creatinine
and urinary TP/C by enhancing NO-induced cGMP
formation/accumulation, as with cavernosal tissue (24).
Cyclosporin A, a potent immunosuppressive agent, causes
nephrotoxicity characterized by similar renal changes to those
reported here, i.e. elevated serum creatinine levels and a
decrease in CrCl (25, 26). FR226807 (Fujisawa Pharmaceutical,
Japan) another PDE-5 inhibitor was found to improve
cyclosporin A-induced nephrotoxicity in spontaneous
hypertensive rats, as did sildenafil (25). This finding suggests
that PDE-5 inhibitors have a beneficial effect on impaired renal
function. These authors also suggested that the effect of
FR226807 was probably due to an increase in cGMP content in
the kidney, rather than via reducing blood pressure.
An important finding from that study was that
cyclosporin A-induced pathological changes in renal
morphological were improved by FR226807. Further work
is required to determine whether vardenafil treatment can
arrest or delay the known renal morphological changes that
are associated with diabetic nephropathy. 
Finally, the present study suggests a possible role for
vardenafil in the treatment of diabetic nephropathy.
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 Introduction 
 Erectile dysfunction (ED) is defined as the inability to 
achieve or maintain an erection sufficiently rigid to allow 
vaginal penetration for satisfactory sexual intercourse 
 [1] . ED is estimated to affect about 1 in 10 adult males  [2] 
and has a substantial impact on family life and employ-
ment  [3] .
 Serotonin (5-hydroxytryptamine, 5-HT) is a mono-
amine transmitter, which was first discovered by Irvine 
Page and his colleagues in 1949. It is stored in both pe-
ripheral endocrine and neuronal cells. 5-HT may be in-
volved in diseases, including depression and hyperten-
sion. The 5-HT receptors are a large and complex family 
of receptors. To date, seven classes (5-HT 1  to 5-HT 7 ) have 
been identified, based on structural and functional char-
acteristics  [4] .
 5-HT neurons are involved in the control of sexual be-
haviour in both humans and animals  [5] . The paraven-
tricular nucleus (brain) via descending serotoninergic ra-
phe-spinal neurons is thought to play a role in penile 
erection  [6] . In summary, central (brain) activation of the 
5-HT 1A  receptor inhibits  [7, 8] , and activation of 5-HT 2A  
and 5-HT 2C  receptor enhances erection  [9–11] . Drugs 
that act in the brain via the 5-HT pathway may affect 
erectile function. 5-HT-specific reuptake inhibitors (e.g. 
paroxetine) increase the incidence of ED  [12] . This is at-
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 Introduction: Serotonin (5-hydroxytryptamine; 5-HT) can 
cause contraction in cavernosal smooth muscle. We further 
evaluated this effect of 5-HT.  Methods: Organ bath studies 
were used.  Results: 5-HT induced a sustained contraction 
occasionally accompanied by a transient relaxation (in 30% 
of rabbit cavernosal tissues) that preceded the contraction. 
Ondansetron and Y-25130 (both 5-HT 3  receptor antagonists) 
but not SB-269970 (a 5-HT 7  receptor antagonist) significant-
ly inhibited or abolished this transient relaxation. Doxazosin 
(dox, an    1 -receptor antagonist) and ketanserin (ketan, a
5-HT 2A  receptor antagonist) significantly inhibited or abol-
ished the sustained contraction. The effects of dox on 5-HT-
mediated contraction were concentration-dependent.  Con-
clusions: Our findings further confirm that the peripheral 
serotonergic pathway may play a part in the erectile process 
via 5-HT 2A  receptor-mediated contractile and 5-HT 3  recep-
tor-mediated relaxant activities. Our results also support the 
findings of human studies, which suggest that both ketan 
and dox may exert beneficial effects on the erectile pro-
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tributed to inhibition of nitric oxide synthase (NOS) ac-
tivity. Furthermore, trazodone, an antidepressant, can 
cause priapism via its major metabolite, metachloro-
phenylpiperazine (a neuronal 5-HT releaser)  [13, 14] .
 At penile level, evidence has emerged of the role of the 
serotonergic pathway in the erectile process. Finberg and 
Vardi  [15] demonstrated an in vivo 5-HT-mediated inhib-
itory action on penile erection in rats due to vasoconstric-
tion of the cavernosal arteries. Also, Esen et al.  [16] showed 
that the in vitro 5-HT-mediated contractile response in 
human penile veins was augmented in patients with veno-
occlusive disease. The involvement of 5-HT 1A   [17, 18] , 5-
HT 1B   [18] and 5-HT 2A  receptors  [17] in contracting caver-
nosal smooth muscle were shown in animal studies. Fur-
thermore, 5-HT 1A , 5-HT 2A  and 5-HT 4  receptors were 
implicated in human erection  [19–21] .  Table 1 summariz-
es the effects on erection of activation of different 5-HT 
receptor subtypes and clinically used serotonergic agents.
 Ketanserin (ketan, 5-HT 2A  receptor antagonist) and 
doxazosin (dox, an    1 -blocker) can exert beneficial effects 
on ED. dox improved ED in combination with either 
sildenafil (silde)  [22] or intracavernosal prostaglandin E 1  
(PGE 1 ) therapy  [23] when either silde or the cavernosal 
therapy alone had failed. Ketan combined with intracav-
ernosal PGE 1  was effective in producing an erection suf-
ficient for sexual intercourse in 76% of patients with ED 
when the PGE 1  therapy alone had failed (n = 45)  [24] . 
Concomitant penile tumescence was noted  [25] in a study 
which showed improved maximum urinary flow rates in 
patients with benign prostatic hyperplasia who were 
treated with ketan.
 A significant increase in 5-HT levels in cavernous se-
rum from flaccidity (113) to tumescence and rigidity and 
also the detumescence phase (123) in normal human sub-
jects was reported  [20] . There were less pronounced 
changes in 5-HT levels in the systemic circulation at all 
stages  [20] . This variation in local 5-HT levels at different 
stages of erection may be important in ensuring detu-
mescence. Therefore, 5-HT may play a physiological role 
in the control of penile flaccidity.
 We further evaluated the role of 5-HT and the effects 
of dox and ketan on the erectile process (using normal 
rabbits).
 Materials and Methods 
 Tissues 
 Cavernosal tissues were obtained from 30 rabbits (New Zea-
land White); their weights were between 2.5 and 3 kg. Their diet 
was standardized (SDS, Whitham, UK) during a week of acclima-
tization. All animals used in these experiments were killed by 
cervical dislocation in accordance with Home Office (UK) per-
mission. Their penises were immediately excised and kept in ice-
cold Krebs solution. The Krebs solution was made up of NaCl 120 
m M , NaHCO 3  25.6 m M , KCl 4.7 m M , CaCl 2  2.5 m M , NaH 2 PO 4  1.2 
m M and glucose 11 m M with a pH of 7.4.
 Materials 
 The following drugs and other materials were supplied by Sig-
ma Chemical Co. (Poole, Dorset, UK): phenylephrine and 5-HT. 
The following chemicals were provided by Bachem Fine Chemi-
cals (Switzerland):  L -N G -nitroarginine. Tocris Cookson Ltd, Bris-
tol (UK), provided the following chemicals: SB-269970, ondanse-
tron, Y-25130, corynanthine, yohimbine and ketanserin. Doxazo-
sin was a gift from Pfizer Pharmaceuticals Group (UK).
 Organ Bath Studies 
 Functional work was performed immediately on obtaining pe-
nile tissue. The tunica albuginea was opened to expose the caver-
nosal tissues. Once the cavernosal tissue was isolated, it was cut 
into approximately 3  ! 4  ! 5 mm strips. The tissues were dis-
sected following the penile trabecular structure. The strips were 
strung up in a vertical organ bath system. Each bath chamber was 
filled with 10 ml of Krebs solution maintained at 37  °  C by a ther-
moregulated circuit and bubbled with a mixture of 95% O 2  and 
5% CO 2 . An initial tension of 2 g was applied and the strips were 
allowed to equilibrate for 1 h without any further mechanical ma-
nipulation.
Table 1. Effect on erection of activation of different 5-HT receptor subtypes (based on animal and human stud-
ies) and clinically used serotonergic agents (see the Introduction for references)
Effect Centrally sited 5-HT
receptor subtype (species)
Peripherally sited 5-HT
receptor subtype (species)
Effect of clinically used
serotonergic drug
Tumescence/erection 5-HT2A (rats)
5-HT2C (rats)
5-HT4 (rabbits, human) Trazodone
Detumescence 5-HT1A (rats) 5-HT1A (rabbits, human)
5-HT1B (rabbits)
5-HT2A (rabbits, human)
Serotonin-specific reuptake
inhibitors, e.g. paroxetine
Doxazosin
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 The cavernosal tissue strip was contracted at the beginning 
and end of every organ bath study with potassium chloride (KCl, 
120 m M ) to ensure tissue viability. The tissue was washed at least 
three times at the start of each experiment and left to recover for 
15 min.
 5-HT 10 –3   M was added to the bath chamber to assess the re-
sponse of cavernosal tissue strips to 5-HT. Accumulated dose-in-
cremental 5-HT-mediated responses were not performed as we 
had previously shown tachyphylaxis of 5-HT with accumulating 
doses in human cavernosal strips. We demonstrated a 43.8% re-
duction of maximal/overall 5-HT contraction with accumulative 
doses (5  ! 10 –7   M , 3  ! 10 –6   M , 10 –5   M , 3  ! 10 –5   M , 10 –4   M and 
10 –3   M ) of 5-HT 30 min following initial same accumulative dos-
es of 5-HT followed by washout  ! 3 ( initial: median: 11.88 mg/
mg, min: 5.83 mg/mg, max: 25.65 mg/mg;  at 30 min: median: 6.68 
mg/mg, min: 3.65 mg/mg, max: 21.29 mg/mg; p  ! 0.02 Wilcoxon 
test, n = 7 each group). Similar 5-HT tachyphylaxis responses 
were also demonstrated by others  [26–30] .
 However, a single-dosage exposure of rabbit cavernosal strips 
to 5-HT 10 –3   M and subsequent same 5-HT re-exposure 30 min 
post-vehicle (distilled water) addition both gave similar 5-HT-
mediated contractile responses with no significant difference 
( table 2 ). Thus, we adopted this single-dosage 5-HT addition in 
our study. The dose of 10 –3   M was chosen as it was shown to give 
optimal results when assessing the responses of 5-HT with and 
without pre-exposure to its antagonists in our previous study 
 [30] .
 5-HT 3  receptor antagonists 10 –5   M (ondansetron (ondan) and 
Y-12530 (Y-3)), 5-HT 7  receptor antagonist 10 –5   M (SB-269970, SB-
7),  L -NAME 10 –4   M (a NOS inhibitor), corynanthine 10 –5   M (co-
ryn;    1 -blocker), yohimbine 10 –5   M (yohim;    2 -blocker), dox 10 –4  
or 10 –6   M (dox;    1 -blocker), ketan 10 –5   M (5-HT 2A  antagonist) or 
distilled water (DH 2 O, as controls) was then added to the bath for 
30 min followed by re-exposure of 5-HT to assess the effect of 
these compounds on the 5-HT-mediated response. All chemical 
agents used in this study are summarized in  table 3 .
 Isometric responses of the tissue were amplified and recorded 
using a Chart 4 Windows programme. The tissue used in the or-
gan bath studies was weighed and expressed as tension mg/mg of 
tissue by dividing the amount of contraction/relaxation occur-
ring on exposure to an agent by the weight of the tissue.
 Statistical Analysis 
 Statistical analysis software (Prism-Graph Pad Inc., USA)
was used for statistical analysis. Comparisons were made using 
the two-tailed non-parametric paired (Wilcoxon) or unpaired
(Mann-Whitney) tests. Significance was at p  ! 0.05.
 Results 
 Results are presented as median (range) of mg tension/
mg of tissue.
 Pattern of 5-HT-Mediated Responses 
 A biphasic 5-HT-mediated response of transient relax-
ation followed by sustained contraction was observed in 
30% of the cavernosal strips used (38 strips of a total of 
125) ( fig. 1 ).
Table 2. 5-HT-mediated contraction of rabbit cavernosal tissues 
before and after the addition of 100 l of distilled water (DH2O; 
n = 8) or ketanserin (ketan; n = 8) 10–5 M (results are presented as 
median (range) in mg tension/mg of tissue)
DH2O
(p > 0.1)
Ketan 10–5 M
(p < 0.02)
5-HT 10–3 M
before addition 30.4 (4.9–107.8) 64.5 (21.5–407.7)
5-HT 10–3 M
after addition 28.5 (3.8–126.9) 0 (0–8.3)
Table 3. Description of agents used in our study apart from
5-HT
Agent Receptor/enzyme acted on
Phenylepherine (PE) 1
Ketanserin (ketan) 5-HT2A
Doxazosin (dox) 1, 5-HT2A
Ondansetron/Y-12530 5-HT3
SB-269970 5-HT7
Corynanthine 1
Yohimbine 2
L-NG-nitroarginine (L-NAME) NOS
The mechanisms of 5-HT-mediated action via its different re-
ceptor subtypes as well as post 1-receptor actions involve activa-
tion of G-protein-coupled phospholipase C on the cavernosal 
membrane. The resulted activated phospholipase C converts 
phosphatidylinositol 4,5-bisphosphate into inositol 1,4,5-tris-
phosphate (IP3) and diacylglycerol. IP3 causes the release of cal-
cium into the cytosol via its receptor binding on the endoplasmic 
reticulum. The overall outcome is the initiation of cavernosal 
contraction due to an increased intracellular concentration of cal-
cium [4, 36]. L-NG-nitroarginine (L-NAME) inhibits nitric oxide 
synthase (NOS), the enzyme which catalyses nitric oxide (NO) 
activity. NO activates soluble guanylate cyclase which leads to an 
elevation of intracellular cyclic guanosine monophosphate 
(cGMP) concentrations. The elevated cGMP levels activate G ki-
nase. The exact mechanism by which elevated cGMP concentra-
tions and activation of G kinase cause cavernosal relaxation is still 
not known. Nevertheless, the final common step is a reduction in 
intracellular calcium levels, which inhibits cavernosal contrac-
tion by preventing the calcium-dependent activation of myosin 
light chain kinase [37].
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 5-HT-Mediated Contractions 
 Consistent 5-HT-mediated (10 –3   M ) contractions were 
demonstrated in the cavernosal strips. The median con-
traction (68.8 (4.9–407.7) mg/mg, n = 125) represented 
34% of the phenylephrine (PE; 10 –4   M )-mediated contrac-
tion (204.1 (18.8–784.4) mg/mg, n = 126) of all strips an-
alysed.
 Establishing that the Vehicle Used (Distilled Water, 
DH 2 O) to Dissolve the Test Compounds Did Not 
Affect 5-HT-Mediated Contractions 
 Experiments with the vehicle (i.e. DH 2 O) used to dis-
solve the substances evaluated in this study revealed a 
similar magnitude of 5-HT-mediated contraction before 
and after adding DH 2 O ( table 2 ).
 Characterization of the 5-HT Receptor Subtype 
Responsible for the Contractile Phase 
 The 5-HT-mediated contraction was inhibited by ket-
an (10 –5   M ) by 100% ( table 2 ). This response was also in-
hibited by dox (10 –4   M)  by 87% and (10 –6   M)  by 63% ( ta-
ble 4 ). 
 Establishing the Non-Involvement of    1 - and
   2 -Receptors in the 5-HT-Mediated Responses 
 Both coryn (10 –5   M ), an    1 -blocker and yohim (10 –5   M ) 
(yohim), an    2 -blocker had no significant effect on 5-HT-
mediated contractions ( table 5 ).
 Characterization of the 5-HT Receptor Subtype 
Responsible for the Relaxation Phase  
 The transient relaxation was inhibited by the 5-HT 3  
antagonists, ondan 10 –5   M and Y-25130 10 –5   M by 100% 
( table 6 ) but not the 5-HT 7  antagonist, SB-269970 10 –5   M 
( table 7 ).
 Effect of a NOS Inhibitor  L -NAME (10 –4   M ) on
5-HT-Mediated Transient Relaxations 
 L -NAME (10 –4   M ) either diminished or abolished the 
5-HT-induced transient relaxation phase ( table 7 ).
 Establishing Tissue Viability at the Beginning and the 
End of the Experiments 
 All cavernosal tissues used in this study showed a sim-
ilar potassium chloride (120 m M )-induced contraction at 
the beginning and the end of the experiments (variability 
 ! 10%). Those with variability in responses  1 10% were 
excluded from the study.
 Discussion 
 We demonstrate a new finding of a biphasic 5-HT-in-
duced response (transient relaxation followed by sus-
tained contraction) in cavernosal tissue obtained from 
healthy rabbits. Previously, Webber et al.  [31] demon-
strated the existence of a biphasic 5-HT-mediated re-
Table 4. 5-HT-mediated contraction of rabbit cavernosal tissues 
before and after the addition of doxazosin 10–4 or 10–6 M (dox;
n = 8 for each concentration). Results are presented as median 
(range) in mg tension/mg of tissue
Dox 10–4 M
(p < 0.01)
Dox 10–6 M
(p < 0.02)
5-HT 10–3 M
before addition 34.6 (16.1–156.1) 71.1 (17.9–100.9)
5-HT 10-3 M
after addition 4.4 (0–136.2) 26.1 (0–55.1)
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 Fig. 1. A representative tracing showing 
the biphasic response following the addi-
tion of 5-HT to rabbit cavernosal (Cav) 
strips. The response was measured in 
grams and was characterized by a tran-
sient relaxation followed by a sustained 
contraction. The arrow shows the tran-
sient relaxation phase. 
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sponse in the tracheal vasculature of sheep although they 
reported a contraction followed by relaxation. In our 
study, however, the transient relaxation only occurred in 
30% of all the tissues analysed. This finding probably re-
flects biological variation in the rabbit population.
 The biphasic response in the rabbit cavernosal tissue 
indicates that the relaxation has a rapid onset, is small in 
magnitude and short lasting when compared with the 
contractile response. It may be that the rapid-onset relax-
ation response modulates the activity of the predominant 
contractile activity so that the overall contractile response 
is gradual and thus, the detumescence process is more 
controlled.
 The prime candidates in mediating the relaxation re-
sponse are the 5-HT receptor subtypes 3 or 7. Kanada et al. 
 [32] showed that a selective 5-HT 3  receptor agonist in-
duced a dose-dependent relaxation of rat ileal circular 
muscle. The 5-HT 7  receptor also has an extensive vascular 
distribution and is responsible for the prominent, persis-
tent vasodilator response to 5-HT in anaesthetized ani-
mals  [4] . In our study, the relaxation response was medi-
ated via the 5-HT 3  and not 5-HT 7  receptor subtype. The 
relaxant responses were inhibited by ondan and Y-25130. 
Ondan is an antiemetic agent which acts on the 5-HT 3  re-
ceptor subtype centrally. It would be of interest to evaluate 
its possible proerectile activity clinically via its action at the 
cavernosal smooth muscle as suggested by our findings. 
 The 5-HT 3  receptor-mediated transient relaxation 
may be NO-dependent since the relaxant responses were 
either diminished or abolished by  L -NAME. Further-
more, studies have shown NO-mediated activity via the 
5-HT 3  receptor (e.g. in the rat ileum)  [32] , neuronal cell 
lines  [33] and rat spinal cord  [34] .
Table 5. 5-HT-mediated contraction of rabbit cavernosal tissues before and after the addition of corynanthine 
(coryn) 10–5 M or yohimbine (yohim) 10–5 M. Results are presented as median (range) in mg tension/mg of tis-
sue
Rabbits (n = 13) Rabbits (n = 9)
5-HT 10–3 M 86.2 (18.7 to 201) 5-HT 10–3 M 83.5 (24.8–243.3)
Coryn 10–5 M and 5-HT 10–3 M 89.5 (24.9 to 155) Yohim 10–5 M and 5-HT 10–3 M 80.7 (38.0–194.3)
Table 6. Transient 5-HT-mediated relaxation of rabbit cavernosal tissues before and after the addition of on-
dansetron (ondan) 10–5 M or Y-12530 (Y-3) 10–5 M (5-HT3 antagonists). Results are presented as median (range) 
in mg tension/mg of tissue (the minus sign denotes relaxation)
Rabbits (n = 3) Rabbits (n = 4)
5-HT 10–3 M –15.2 (–47.9 to –13.4) 5-HT 10–3 M –39.1 (–68.6 to –12.1)
Ondan 10–5 M and 5-HT 10–3 M 0 (0 to 0) Y-3 10–5 M and 5-HT 10–3 M 0 (0 to 0)
Table 7. 5-HT-mediated transient relaxation of rabbit cavernosal tissues before and after the addition of SB-
269970 10–5 M or L-NAME 10–4 M. Results are presented as median (range) in mg tension/mg of tissue (the mi-
nus sign denotes relaxation)
SB-269970 10–5 M (p > 0.2; n = 9) L-NAME 10–4 M (p < 0.02; n = 5)
5-HT 10–3 M before addition 37.6 (13.6 to 109.6) –39.5 (–84.4 to –11.6)
5-HT 10–3 M after addition 40.3 (16.8 to 113.1) 0 (–25 to 0)
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 In our study, ketan inhibited the contractile response 
mediated by 5-HT on the corpus cavernosum suggesting 
the presence of 5-HT 2A  receptors which mediate smooth 
muscle contraction. Also, dox had a similar effect as ket-
an on the cavernosal smooth muscle. The latter finding 
suggests that dox has a 5-HT  inhibitory action. This can 
also be inferred from previous studies of the 5-HT-medi-
ated effects of dox in human platelets and rabbit bladder 
detrusor muscle  [30, 35] .
 Our studies demonstrated that 5-HT 10 –3   M does not 
act on    1 - or    2 -receptors as coryn and yohim respec-
tively have no significant effect on the 5-HT-mediated 
contraction. Therefore, the antagonistic effect of ketan 
and dox on 5-HT-mediated contraction is via 5-HT and 
not   -receptors.
 The cavernosal basal tone (CBT) is maintained by the 
interaction between contractile (including 5-HT) and re-
laxant (e.g. NO) pathways. The cavernosal smooth mus-
cle, like other muscles, has a basal tone at rest. The CBT 
maintains the flaccidity of the penis. Tumescence occurs 
when the CBT is lowered to a ‘trigger point’ to allow ad-
equate opening of the cavernosal lacunar spaces (comple-
ments the veno-occlusive mechanism) and hence the 
pooling of blood resulting in erection. Likewise, the re-
verse occurs during the detumescence process to return 
the ‘relaxed’ CBT to the normal physiological contracted 
(resting) state. Our findings suggest that erection may be 
enhanced by promoting relaxant pathways such as acti-
vation of 5-HT 3  receptor subtype and/or inhibiting the 
contractile pathways such as activation of 5-HT 2A  recep-
tors. 
 In conclusion, our findings support the evidence that 
5-HT plays a role in the erectile process via 5-HT 2A  recep-
tor-mediated contractile action. More studies are needed 
to further clarify the role of 5-HT 3  receptor-mediated re-
laxant activity on the erectile process. 5-HT 2A  receptor 
antagonists (e.g. ketan) and possibly a 5-HT 3  receptor  ag-
onist (e.g. ondan) as well as dox may be beneficial in the 
treatment of ED as part of a multi-therapy regimen (when 
monotherapy fails) via 5-HT-dependent mechanisms 
(rather than exclusively via    1 -adrenergic blockade as for 
dox). 
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ABSTRACT: Penile erection results from the balance between
relaxation and contractile mechanisms of the corpus cavernosum.
Only a few studies suggest a role for endogenous contractile agents
such as 5-hydroxytryptamine (5-HT). Our aim was to confirm the
possible role of 5-HT in human erection. The effect of 5-HT on
human cavernosal tissues, as well as those of doxazosin (shown
previously to have 5-HT inhibitory action), ketanserin (5-HT(2A)
receptor antagonist), NAN-190 (5-HT(1A) receptor antagonist), and
SB 203186 (5-HT(4) receptor antagonist) on 5-HT-mediated effects,
were assessed using the organ bath technique, including electrical
field stimulation study (EFS). Results are presented as median (mg/
mg 5 mg contraction/mg of tissue). Consistent 5-HT-mediated
(1023 M) contractions were demonstrated (n 5 18; 63 mg/mg).
These contractions were inhibited with ketanserin by 90% (n 5 8),
NAN-190 by 68% (n 5 12), and SB 203186 by 55% (n 5 12).
Doxazosin showed a similar 5-HT inhibitory action in a concentration-
dependent manner (1024 M; 94% reduction; n 5 8, 1026 M; 68.3%
reduction; n 5 8). Our EFS studies indicated the presence of
neuronally derived 5-HT and that a majority of the nonnoradrenogenic
contraction (54%) was mediated via 5-HT(2A) receptors. These
findings suggest that 5-HT may play a role in the human
detumescence process via 5-HT(1A), 5-HT(2A), and 5-HT(4)
receptors. Neuronally released 5-HT is probably an important
contractile neurotransmitter in the erectile process. Doxazosin,
ketanserin, and 5-HT(1A) and 5-HT(4) receptor antagonists may
be useful as part of combination therapy used to treat erectile
dysfunction.
Key words: 5-hydroxytryptamine, erectile dysfunction, corpus
cavernosum, cavernosal tone.
J Androl 2006;27:679–685
E rectile dysfunction (ED) is broadly defined as theinability to achieve or maintain an erection
sufficiently rigid for satisfactory sexual intercourse
(NIH Consensus Development Panel on Impotence,
1993). ED affects as many as 50% of men over the age of
40 years to some degree and has substantial impact on
quality of family life (Carson, 2004).
Serotonin (5-hydroxytryptamine, 5-HT) is a mono-
amine transmitter found with its receptors both in the
central and peripheral nervous system (CNS/PNS), as
well as in a number of nonneuronal cells in the gut,
cardiovascular system, and blood. 5-HT is one of the
oldest neurotransmitters in evolution. It has been
implicated in the etiology of numerous disease states,
including depression, anxiety, hypertension, and irrita-
ble bowel syndrome. 5-HT receptors are divided into 7
distinct classes (5-HT(1) to 5-HT(7)) based on their
structural and functional characteristics. These recep-
tors are part of the G-protein-coupled receptor (GPCR)
superfamily, with the exception of the 5-HT(3) receptor,
which is a ligand-gated ion channel (Martin et al, 1994).
5-HT neuron participation in the control of sexual
behaviour, both in humans and in animals, is well
established (Hull et al, 2004). Specifically, Bancila et al
(2002) demonstrated a possible role of the paraventri-
cular nucleus (brain) in penile erection through the
control of descending serotonergic raphe-spinal neurons.
In general, central (brain) activation of the 5-HT(1A)
receptor inhibits (Ahlenius et al, 1989; Rehman et al,
1999), and activation of 5-H(2A) and 5-HT(2C) receptor
facilitates, erection (Steers et al, 1990; Bancila et al, 1999;
Brotto et al, 2000). Central acting drugs that influence the
5-HT pathway can affect erectile function. For example,
serotonin-specific reuptake inhibitors such as paroxetine
can increase the incidence of ED due to inhibition of
nitric oxide synthase (NOS) activity (Angulo et al, 2001).
Also, trazodone, an antidepressant, which exerts its effect
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via its major metabolite, metachlorophenylpiperazine (m-
cpp, a neuronal 5-HT releaser) can cause priapism
(Myrick et al, 1998; Rothman et al, 2002).
Peripherally, evidence has emerged of the involvement
of the serotonergic pathway in the erectile process.
Previous studies on penile vessels demonstrated an in
vivo 5-HT-mediated inhibitory action on penile erection
in rats due to vasoconstriction of the cavernosal arteries
(Finberg et al, 1990). The in vitro 5-HT-mediated
contractile response in human penile veins was aug-
mented in patients with veno-occlusive disease (Esen et
al, 1997). Animal studies indicated the involvement of 5-
HT(1A) (Hayes et al, 2002; Furukawa et al, 2003), 5-
HT(1B) (Hayes et al, 2002), and 5-HT(2A) receptors
(Furukawa et al, 2003) in contracting cavernosal smooth
muscle. In addition, Uckert et al (2003) had shown 5-
HT(1A)–mediated contractile response (in vitro) in
human corpus cavernosal strips. A human study by
Hayes et al (1999) also suggested the presence of 5-
HT(4) receptors in cavernosal muscle.
Doxazosin (an alpha-1–blocker shown to have 5-HT
inhibitory action (Khan et al, 2000; Jagroop et al, 2001)
and ketanserin (5-HT(2A) receptor antagonist) have
been shown to have a beneficial action on ED.
Doxazosin also acts on ED in combination with either
sildenafil (de Rose et al, 2002) or intracavernosal
prostaglandin E(1) therapy (Kaplan et al, 1998) when
either sildenafil or the cavernosal therapy alone has
failed. The combined intracavernosal injection therapy
of ketanserin and prostaglandin E(1) was effective in
producing an erection sufficient for sexual intercourse in
76% of patients with ED when the prostaglandin E(1)
therapy alone had failed (n 5 45; Mirone et al, 1996).
Petersen et al (1985) noted concomitant penile tumes-
cence in their study, which showed improved maximum
urinary flow rates in patients with benign prostatic
hyperplasia who were treated with ketanserin.
Since most functional (organ bath) studies were
performed on animals, we aimed to further evaluate
the involvement of 5-HT in the human erectile process
via 5-HT(1A), 5-HT(2A), and 5-HT(4) receptors. We
also evaluated whether doxazosin exhibits a protumes-
cence effect.
Materials and Methods
Tissues
Human penile organs were obtained from patients undergoing
gender reassignment surgery at Charing Cross Hospital,
London, United Kingdom (15 patients, age range 23–57,
mean age 30). Approval was obtained from the Riverside
Ethics Committee, and all the patients gave their informed
consent prior to surgery. Their penile organs were excised and
immediately placed in Krebs solution and kept in an ice-
containing box. The Krebs solution was made up of NaCl
120 mM, NaHCO3 25.6 mM, KCl 4.7 mM, CaCl2 2.5 mM,
NaH2PO4 1.2 mM, and glucose 22 mM with a pH of 7.4.
All patients underwent gender reassignment surgery and had
no significant previous illness (including diabetes) and were
not on any medication apart from estrogen for 2 years.
However, the estrogen therapy was discontinued 2 months
prior to surgery.
Materials
The following drugs and other materials were supplied by
Sigma Chemical Co. (Poole, Dorset, United Kingdom):
atropine hydrochloride, guanethidine, indomethacin, and
phenylephrine. Tetrodotoxin was provided by Bachem Fine
Chemicals (Switzerland). Tocris Cookson Ltd, Bristol (United
Kingdom), provided the following chemicals: corynanthine,
yohimbine, NAN-190, SB 203186 and ketanserin. Doxazosin
and 5-hydroxytryptamine were gifts from Pfizer (United
Kingdom).
Organ Bath Studies
Tissue Preparation—The tunica albuginea was opened to
expose the cavernosal tissues. Once they were isolated, the
cavernosal tissue was cut into 56566-mm strips. The tissues
were dissected following the penile trabecular structure. The
strips were strung up in vertical organ bath systems. Each bath
chamber was filled with 10 ml of Krebs solution maintained at
37uC and continuously gassed with a mixture of 95% O2 and
5% CO2. An initial tension of 2 g was applied, and the strips
were allowed to equilibrate for 1 hour without any further
mechanical manipulation (Thompson et al, 2001).
Establishment of 5-HT-Mediated Response—Adding 5-HT
1023 M to the bath chamber assessed the response of
cavernosal tissue strips to 5-HT. Accumulated dose-incremen-
tal 5-HT-mediated responses were not performed, as we had
previously demonstrated tachyphylaxis of 5-HT with accumu-
lative doses in human cavernosal strips. Specifically, we
showed 43.8% reduction of maximal/overall 5-HT contraction
with accumulative doses (5 6 1027 M, 3 6 1026 M, 1025 M,
3 6 1025 M, 1024 M, and 1023 M) of 5-HT 30 minutes
following initial same accumulative doses of 5-HT followed by
washout6 3 (initial: median 11.88 mg/mg, minimum 5.83 mg/
mg, maximum 25.65 mg/mg; at 30 minutes: median 6.68 mg/
mg, minimum 3.65 mg/mg, maximum 21.29 mg/mg; P , .02
Wilcoxon test, n 5 7 each group). Others had also shown
similar 5-HT tachyphylaxis responses (Sicuteri, 1983; Javid et
al, 1999; Whalen et al, 2000; Lopez-Tudanca et al,
2003). However, a single-dosage exposure of human caver-
nosal strips to 5-HT 1023 M and subsequent same 5-HT
reexposure 30 minutes after vehicle (distilled water) addition
both gave similar 5-HT–mediated contractile responses, with
no significant difference (Table 1). Thus, this single-dosage 5-
HT addition was adopted in our study. The dose of 1023 M
was chosen because it was shown to give optimal results when
assessing the responses of 5-HT with and without preexposure
to its antagonists in our previous study (Khan et al, 2000).
Characterization of 5-HT Receptor Subtype—The effect of
distilled water, NAN-190 (1025 M; 5-HT(1A) receptor antag-
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onist), ketanserin (1025 M; 5-HT(2A) receptor antagonist), SB
203186 (1025 M; 5-HT(4) receptor antagonist), corynanthine
(1025 M; alpha(1) receptor blocker), yohimbine (1025 M;
alpha(2) receptor blocker) and doxazosin (1024 and 1026 M;
alpha(1) receptor blocker) on 5-HT-mediated responses were
also assessed. This was carried out by adding the substance
concerned including distilled water (DH2O) (as controls) to the
bath after initial exposure to 5-HT 1023 M. The bath was then
left for 30 min prior re-exposure to 5-HT 1023 M.
Electrical Field Stimulation (EFS) Studies to Assess Possible
Neuronally Released 5-HT—EFS studies were also carried out
to assess the effect of ketanserin on the possible neuronally
released 5-HT in cavernosal tissues. Each tissue strip was
positioned between 2 metal rings connected to an electrical
circuit and was also subjected to an applied tension of 2 g for
1 hour. Tissues were then exposed to atropine 1025 M,
guanethidine 5 6 1026 M, L-NAME 3 6 1024 M, and
indomethacin 1026 M (by adding the substances to the
organ baths) to inhibit the parasympathetic, sympathetic,
NO, and prostaglandin pathways, respectively. This treat-
ment would enable the EFS studies to unmask any non-
adrenergic-mediated contraction, which could include 5-HT–
induced contraction. The tissues were left for 30 minutes
following the addition of these substances. Electrical currents
of increasing intensity (0.5, 1, 2, 5, 8, 16, and 32 Hz) were
applied across the tissue strips. Each stimulus was applied for
5 seconds, with a rest interval of 2 minutes between each
stimulus. Tissue strips with contractile responses were then
exposed to ketanserin 1025 M. After 30 minutes of exposure
to ketanserin, the EFS (described above) were repeated in the
tissues concerned to assess the possible neuronal 5-HT–
mediated contractions. Tetrodotoxin 1026 M, a neurotoxin,
was used to determine the magnitude of contractions related to
direct muscle stimulation as opposed to neuronal-mediated
contraction. Tetrodotoxin was added to organ baths, and the
tissue strips were exposed for 20 minutes before EFS was
started. This was the last stage of each EFS study. We had
previously shown that repeated EFS 6 3 did not cause
desensitization of the tissue (Calvert et al, 2001; Banks et al,
2006).
Establishing Tissue Viability at the Beginning and the End of
the Experiments—All cavernosal tissues used in this study
showed a similar potassium chloride (120 mM)-induced
contraction at the beginning and the end of the experiments
(variability, 10%). Those with variability in responses. 10%
were excluded from the study.
Measurement of Tissue Response—Isometric responses of
the tissue were amplified and recorded using a Chart 4
Windows program. The tissue used in the organ bath was
weighed and this value recorded. The contractile/relaxant
response of the tissue to a contractile, relaxant, or drug agent
was reported in mg/mg (contraction/mg of tissue) by dividing
the amount of contraction/relaxation occurring on exposure to
an agent by the weight of the tissue concerned.
Statistical Analysis
A statistical analysis software (PRISM, Graph Pad Inc., San
Diego, Calif) was used for the statistical analysis of the human
functional studies. Comparisons were made using the 2-tailed
nonparametric paired (Wilcoxon) test.
Results
Consistent 5-HT–mediated (1023 M) contractions from
baseline recordings were demonstrated in human
cavernosal tissues (n 5 25, median 63 mg/mg, range
10.2–178.5 mg/mg).
Experiments with the vehicle (ie, distilled water) used
to dissolve the substances evaluated in this study
revealed a similar magnitude of 5-HT–mediated con-
traction before (median 98.8 mg/mg) and after (median
92.0 mg/mg, n 5 14) adding DH2O (P . .1, Table 1).
These contractions were inhibited by ketanserin by 91%
(n 5 11, Table 1), NAN-190 by 68% (n 5 12, Table 1),
and SB 203186 by 55% (n 5 12, Table 1).
Doxazosin showed a similar 5-HT inhibitory action in
a concentration-dependent manner (1024 M; 94% re-
duction; n 5 8, 1026 M; 84% reduction; n 5 10,
Table 2). The doxazosin response was not attributable
to alpha blockade, since alpha-1 and 2 antagonists
(corynanthine and yohimbine) had no significant effect
on 5-HT–induced contractions (Table 2).
Optimal human cavernosal contractions of 6.3 mg/mg
were observed at 32 Hz in the EFS studies where tissues
were preexposed to indomethacin, guanethidine, atro-
pine, and L-NAME (Figures 1 and 2). The subsequent
addition of ketanserin led to abolition of 54% of the
EFS-induced cavernosal contractions (Figure 1). Add-
ing tetrodotoxin inhibited a further 34% of these
reduced EFS-induced contractions (Figure 1).
Table 1. 5-HT-mediated contraction of human cavernosal tissues before (control) and after the addition of a chemical agent
(antagonist or distilled water [vehicle]). Results are presented as median (range) in mg tension/mg of tissue. N denotes number
of patients studied. Wilcoxon test is used for statistical analysis. Significance is described as P , .05
Control Antagonist Treatment N P value
98.8 (8.9–177.5) 92.0 (8.3–187.9) Distilled water (vehicle) 14 . .1
53.7 (7.2–143.3) 4.6 (0–32.3) 1025 M Ketanserin 11 , .02
107.6 (57.3–268.5) 34.5 (3.6–75.6) 1025 M NAN-190 12 , .01
107.8 (45.8–347.9) 48.7 (10.6–203.3) 1025 M SB 203186 12 , .01
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Discussion
Our findings show for the first time that there is possibly
preterminal neuronal storage of 5-HT in the human
corpus cavernosum, which is released by EFS and acts
on 5-HT(2A) receptors. This is shown following
blockade of the effects of prostaglandin, neuronal- and
endothelial-derived NO, sympathetic and parasympa-
thetic pathways with indomethacin, L-NAME, guaneth-
idine, and atropine, respectively, prior to EFS with and
without ketanserin addition. The EFS-contractile re-
sponses in our study are nonnoradrenergic, as guaneth-
idine leads to effective inhibition of noradrenaline
release from sympathetic nerves. The neuronally re-
leased 5-HT acting on 5-HT(2A) receptors comprises
54% of the nonnoradrenergic (neuronal)-mediated
human cavernosal contraction. Thus, neuronally re-
leased 5-HT is probably a contractile neurotransmitter
in the erectile process in addition to noradrenaline (NA).
This is in contrast to the findings of Uckert et al (2003).
They concluded in their study that 5-HT did not
contribute to neuronal derived function of the human
corpus cavernosum (HCC). They added a 5-HT(1A)
antagonist following EFS of precontracted cavernosal
strips with phenylepherine. They showed a brief re-
Table 2. 5-HT–mediated contraction of human cavernosal tissues before (control) and after the addition of a chemical agent
(antagonist or distilled water [vehicle]). Results are presented as median (range) in mg tension/mg of tissue. N denotes number
of patients studied. Wilcoxon test is used for statistical analysis. Significance is described as P , .05
Control Antagonist Treatment N P value
49.9 (7.8–179.5) 8.0 (1.7–24.1) 1026 M Doxazosin 10 , .02
59.8 (10.1–84.6) 3.4 (0–30.9) 1024 M Doxazosin 8 , .02
97.5 (25.3–205) 99.4 (27.9–173) 1025 M Corynanthine 13 . .1
91.2 (26.6–230.1) 93.7 (35.8–242.6) 1025 M Yohimbine 9 . .1
Figure 1. The effects of increasing frequencies of electrical field stimulation (median 6.3, range 3.0–89.7, control) on human corpus
cavernosum (n 5 8) pretreated with atropine 1025 M, guanethidine 5 6 1026 M, L-NAME 3 6 1024 M, and indomethacin 1026 M and the
changes seen in EFS following the exposure to ketanserin (ketan) 1025 M (median 2.9, range 1.3–5.4, P 5 .001 versus control) and then plus
tetrodotoxin (TTX) 1026 M (median 1.9, range 0.9–4.6, P 5 .001 versus control). Contractions are expressed as median and range values (mg
tension/mg of tissue).
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laxation response (attributed to neuronal nitric oxide
release) with each EFS, which was not altered following
subsequent addition of the 5-HT antagonist. If neuron-
ally derived 5-HT acts on 5-HT(1A) receptors, this
method did not guarantee effective blockage of the 5-
HT(1A) receptors, as activation of the receptors by
neuronally derived 5-HT would have occurred prior to
the addition of the antagonist. It may also be that 5-
HT(2A) (shown in our study) and not 5-HT(1A)
receptors contribute to neuronal-derived 5-HT action
on HCC.
Uckert et al (2003) also reported a significant increase
in 5-HT levels in cavernous serum (mean ng/ml) from
flaccidity (113) to tumescence and rigidity (140 and 141,
respectively) and also the detumescence phase (123) in
normal human subjects. There were less pronounced
changes in 5-HT levels in the systemic circulation at all
stages. This variation in local 5-HT levels in different
stages of erection may be important in ensuring
detumescence. It is possible that neuronally released 5-
HT contributes to this variation. Therefore, 5-HT may
have a physiological role in the control of penile
flaccidity.
We show in our studies that 5-HT 1023 M does
not act on alpha-1 or alpha-2 receptors, as corynanthine
and yohimbine, respectively, have no significant effect
on the 5-HT-mediated contraction. Therefore, the
antagonistic effects of ketanserin and doxazosin on 5-
HT-mediated contraction are via 5-HT and not alpha-
receptors.
We provide a new finding of the effect of a 5-HT(2A)
receptor antagonist on HCC, suggesting possible anti-
erectile role of the 5-HT(2A) receptor subtype. Further-
more, we support previous evidence (Mirone et al,
1996; De Rose et al, 2002) that doxazosin and ketanserin
may be beneficial in the treatment of ED (findings
presented at the 2nd International Consultation on
Erectile and Sexual Dysfunction in Paris, 28th June–1
July 2003) as well as that the 5-HT(1A) receptor subtype
might play a role in human detumescence (Uckert et al,
2003). Our previous and present studies have demon-
strated that doxazosin had 5-HT inhibitory action
not just in the human corpus cavernosum but also in
rabbit bladder detrusor muscle (Khan et al, 2000)
and human platelets (Jagroop et al, 2001). These suggest
that doxazosin also acts on 5-HT receptors. Our studies
set the precedent for future studies to evaluate the
mechanisms of 5-HT-inhibitory actions by doxazosin.
The possible serotonergic-related action noted with
doxazosin raises the question whether other alpha-
blockers (e.g. alfuzosin or tamsulosin) exert a 5-HT-
mediated effect. It is possible that similar bioprofile
of serotonergic-induced action to that of doxazosin
might account for the improvement in erection in men
with lower urinary tract symptoms and concomitant
sexual dysfunction treated with alfuzosin (van Moorse-
laar et al, 2005). Apart from erection, this possible
blocking of 5-HT–mediated effect by alpha-blockers
may also simultaneously improve bladder symptoms
related to bladder outlet obstruction (Khan et al, 2005).
Therefore, the beneficial effect of alpha-blockers on the
bladder may not be exclusively mediated via alpha-
receptor.
Our study suggests a contractile effect on HCC via 5-
HT(4) receptors, which is in contrast to what was
observed in rabbits (Furukawa et al, 2003), where a 5-
HT(4) receptor antagonist potentiated 5-HT-mediated
contraction. Therefore, 5-HT(4) receptor activation may
contribute to cavernosal relaxation in rabbits. These
findings indicate interspecies variability in 5-HT–medi-
ated action via different receptor subtypes.
The potency of 5-HT receptor–mediated responses
according to different receptor subtypes are in the order
(% inhibition of 5-HT-mediated contraction by its
respective antagonist): 5-HT(2A) 90% . 5-HT(1A)
68% . 5-HT(4) 55%. This order indicates the relative
importance of each of the 3 receptors in affecting the 5-
HT-mediated contraction, with the dominant receptor
being 5-HT(2A). Therefore, 5-HT(2A) may play a great-
er part in the antitumescence process compared with 5-
HT(1A) or 5-HT(4) receptor subtypes.
Figure 2. A representative tracing showing the contractile response
following electrical field stimulation (EFS: 2, 5, 8, 16, 32, 64 Hz)
of human cavernosal strips (preexposed to atropine 1025 M, gua-
nethidine 5 6 1026 M, L-NAME 3 6 1024 M, and indomethacin
1026 M). Addition of ketanserin (1025 M), a 5-HT2 antagonist,
reduced the EFS-induced contractions. The response was measured
in grams (g).
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Erection depends on the balance of local contractile
and relaxant forces in the corpus cavernosum (Cellek,
2000; Kim et al, 2000). Tumescence/erection is favored if
the overall relaxant force dominates to lower cavernosal
tone to a critical level and vice versa. Therefore, it is not
inconceivable that by targeting the contractile pathway
such as 5-HT as well as promoting a relaxant pathway
(eg, with a phosphodiesterase-5 (PDE-5) inhibitor), the
critical level will be achieved more readily in patients
with ED. Our findings indicate that doxazosin and 5-
HT(1A), 5-HT(2A) (such as ketanserin), and 5-HT(4)
receptor antagonists may be useful as part of a multi-
therapy regime, especially when a single therapy with
a PDE-5 inhibitor fails.
Normal HCC is limited in its availability. In previous
studies, HCC tissues were obtained from patients with
Peyronie disease or diabetes or undergoing penile
prosthesis implants for ED (Mirone et al, 2000). These
samples are clearly pathological. Mirone et al (2000) and
Rees et al (2001) proposed the use of HCC tissue
obtained from patients undergoing gender reassignment
surgery. These patients are normally on estrogen for
2 years prior to withdrawal 2 months before their
surgery, as with the majority of patients involved in
our study. We cannot exclude the effect of estrogen on
the cavernosal tissue, as Adaikan et al (2003) showed
that estrogen causes pathophysiological changes in
erectile function in rats. However, in our study, 1 patient
who refused estrogen therapy prior to surgery had
similar 5-HT responses (with or without pre-exposure to
its antagonists) to those on estrogen. Furthermore, those
gender-reassigned patients previously on estrogen seem
to have "normal" erections (indicated by the presence of
early morning erections), based on clinical interviews
post–estrogen withdrawal prior to surgery.
Future work should involve immunohistochemical
studies using cavernosal tissue to further identify/
confirm the 5-HT receptor subtype and distribution as
well as their anatomical location (eg, nerve terminals
and/or endothelium).
In conclusion, neuronally-released 5-HT may play
a role in the human detumescence process. Doxazosin
and 5-HT(1A), 5-HT(2A) (such as ketanserin) and 5-
HT(4) receptor antagonists possess proerectile effects
that may prove useful in the treatment of ED, possibly
in combination with other therapy.
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